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ABSTRACT 
 
Streptococcus pneumoniae, a member of the diverse microbial community 
of the human nasopharynx, is subjected to competitive interactions. Since 
colonization is a prerequisite for pneumococcal pathogenesis, understanding the 
dynamics of bacterial competition is important for identifying factors that aid in 
colonization and carriage. To eliminate competitors, pneumococcus is known to 
secrete antimicrobial peptides or bacteriocins.  Pneumococcal bacteriocins and 
their role in competition have been well characterized. However, a class of 
modified bacteriocins named lantibiotics, and their role in promoting 
pneumococcal competition is less well understood. Though several lantibiotic loci 
have been identified in pneumococcus, none have been found with antimicrobial 
activity. Recently, our laboratory identified a clinical isolate of pneumococcus, 
P174, with a broad spectrum of inhibitory activity attributed to a novel lantibiotic 
locus, termed pneumolancidin (pld). In addition to encoding genes required for 
the modification, processing, regulation and immunity to lantibiotic peptides, four 
open reading frames predicted to encode four highly homologous lantibiotic 
peptides were also found. This posed the question of whether the Pld peptides 
were redundant in function or had specialized roles. Lantibiotic peptides are 
known to function as antimicrobials and autoinducers. To determine the role of 
each peptide as it relates to inhibition and induction, individual in-frame peptide 
  xii 
deletions were constructed. Strains carrying the mutation were assayed for their 
ability to inhibit the growth of other strains and their ability to upregulate the pld 
locus. The first three peptides, PldA1-3, were found to be required for signaling 
while PldA4 was found to be dispensable. Because upregulation of the locus is 
needed to determine whether specific peptides were involved in inhibition, the 
ability of the peptide deletion strains to inhibit could not be evaluated. However, a 
serendipitous mutant, P174act, was discovered that allowed for distinct 
phenotypes to be observed for each of the Pld peptide deletion strains. Through 
structural elucidation, it was found that PldA1 and PldA3 are structurally similar 
yet have specialized roles in signaling and inhibition, respectively. The Pld 
peptides represent a novel strategy for bacterial competition and provide insight 






















Lantibiotics are a class of bacteriocins produced by many Gram-positive bacteria 
with activity primarily against other Gram-positive strains. Lantibiotics undergo 
extensive posttranslational modifications that are required for activity as 
antimicrobials and as autoinducers that upregulate their own expression. They 
are promising for use as potential therapeutics for many reasons. First, 
lantibiotics are quite potent; nanomolar concentrations are typically sufficient to 
inhibit bacterial growth. Second, many lantibiotics demonstrate a dual 
mechanism of action, which make it more difficult for target bacteria to develop 
resistance. While these key features could certainly prove useful in the treatment 
of antibiotic resistant bacteria, the reliance of lantibiotics on intracellular 
machinery for their functionality make lantibiotics notoriously difficult to 
synthesize and current methods of purification from host cells are laborious. 
Understanding how the production of lantibiotic peptides is regulated within the 
cell will be useful to improve output and purification. Likewise, characterization of 
the protein structures and how those structures relate to overall function will be 
fundamental to our understanding of these entities as therapeutics and will 
provide new insight into the design of innovative, potentially breakthrough 
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antimicrobials. This review will focus on the biosynthesis, regulation, and 
structure of lantibiotic peptides produced by S. pneumoniae and closely related 
Gram-positive bacteria. 
.
1.1 Bacterial Competition 
Bacteria often exist in polymicrobial communities found either in the 
environment or in the host. To survive, bacteria have evolved multiple 
mechanisms to promote either cooperative or competitive relationships for 
access to limited resources. Cooperative interactions result in beneficial 
outcomes to all groups involved. Competitive interactions, on the other hand, 
result in a negative outcome for one group and can occur in two ways, indirect 
(exploitative) or direct (interference). Indirect competition refers to a bacterial 
cell’s ability to utilize nutrients more efficiently than neighboring bacteria, 
preventing it from being able to utilize the required nutrients essential for survival. 
This mechanism has been noted to play a role in shaping the gut microbiota. As 
an example, commensal Escherichia coli strains were able to outcompete 
pathogenic enterohemorrhagic E. coli (EHEC). This was shown using a mouse 
model in which mice were treated with streptomycin to eliminate facultative 
anaerobic bacteria so that specific E.coli strains can introduced into the mouse 
and competitive experiments can be performed. Commensal E. coli was shown 
to confer a protective effect by utilizing sugars more efficiently than EHEC [1, 2]. 
Direct competition refers to bacteria producing specific factors or altering abiotic 
factors that can that directly inhibit their competitors’ growth. An example of direct 
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competition through manipulation of abiotic factors can be seen with a recently 
discovered Streptococcus species found in the oral cavity that has the capacity to 
the pH of the environment through increased arginine catabolism [3]. Higher pH 
values inhibit the growth of Streptococcus mutans, a caries causing pathogen, 
effectively eliminating the competition by creating an inhospitable environment 
[3].  In addition to altering abiotic variables, bacteria can also produce factors that 
are directly (or actively) inhibitory to bacteria. Production of antimicrobial peptides 
is one common strategy used by bacteria.  
 
1.2 Bacteriocins 
Bacteriocins are antibiotics that are ribosomally synthesized small 
peptides. Bacteriocins exert an antimicrobial effect on either a wide or narrow 
range of competing bacteria [4]. Nearly all bacteria that have been studied 
encode at least one bacteriocin in their genome, however, the Gram-positive 
lactic acid bacteria (LAB) are the best-known producers of bacteriocins [5].  
The LAB, which comprise the Lactobacillus, Streptococcus, Leuconostoc, 
Pediococcus, and Lactococcus genera primarily, are named for their ability to 
convert glucose into lactic acid.  This property makes them useful in the food 
industry, not only for their ability to ferment certain foods, but also for their ability 
to prevent spoilage and colonization by pathogenic bacteria by either production 
of bacteriocins and/or lowering the pH through lactic acid production. Some of 
the LAB or their bacteriocin products can be added to food because they fall into 
the category of generally recognized as safe by the food industry. Bacteriocins 
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that are produced by LAB can be divided into two classes: Class I are post- 
translationally modified lanthionine-containing peptides (otherwise known as the 
lantibiotics),and Class II are unmodified, non-lanthionine containing peptides [4]. 
Class II bacteriocins can be further divided into four subclasses: Class IIa are 
known as pediocin-like and are characterized by their listericidal activity, class IIb 
are two peptide bacteriocins, class IIc are circular bacteriocins, and class IId are 
other linear, non-pediocin single peptide bacteriocins.  
The class I lantibiotics will be the main focus of this introduction because 
of their potent antimicrobial activity. With the rise of antibiotic resistant bacteria, 
there is a demand for new antimicrobials. One option that is being pursued is the 
use of lantibiotics to treat bacterial infections. Lantibiotics undergo 
posttranslational modifications that are required for their antimicrobial activity. 
These modifications impart additional benefits including resistance to proteolytic 
degradation and stability at high temperatures. Most importantly, resistance to 
lantibiotics is more difficult to acquire because of their dual mechanism of action 
in killing bacteria, a combination of binding to lipid II and pore formation in the 
bacterial membrane. Further understanding of how these lantibiotic peptides 




 Approximately100 lantibiotics have been discovered and it is expected 
that this number will continue to grow as more microbial genomes are sequenced 
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and mined for lantibiotic associated genes. Lantibiotics undergo extensive 
posttranslational modifications that are required for their function as both an 
antimicrobial and auto-inducer. The following sections will explore the 
biosynthesis, regulation, structures, and mechanisms of self- immunity of some 
of the best-characterized lantibiotics. 
1.3.1 Biosynthesis of lantibiotics 
 Lantibiotic loci can be found encoded on the chromosome, often as part of 
an intergrative conjugative element (ICE) or on an extra chromosomal plasmid. 
This suggests that lantibiotic loci can be transmitted through horizontal gene 
transfer between strains and species. Lantibiotics are subject to extensive 
posttranslational modifications that result in the creation of lanthionine or 
methyllanthione residues. The name lantibiotic arises from the presence of the 
unusual residue lanthionine combined with the antimicrobial properties of the 
lanthione containing peptides, eg, lanthionine-containing antibiotics [6].  The 
nomenclature for generic lantibiotic genes uses lan, or a specific abbreviation of 
the lantibiotic, i.e. nis for nisin, followed by a letter to designate the function of the 
gene product. The lantibiotic is first translated into a prepeptide that is encoded 
by lanA. The prepeptide lantibiotic has an N-terminal leader sequence that is 
required for recognition by the modification machinery and for transport outside 
of the cell and a C-terminal propeptide that will be modified. Lantibiotics can be 
divided into three different classes depending on their modification machinery 
and function [7, 8]. 
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 Class I lantibiotics are modified by two separate modification enzymes 
encoded by lanBC. In the case of nisin, the prototypical lantibiotic produced by 
Lactococcus lactis and discovered in 1928, modification is catalyzed by NisB and 
NisC [9, 10]. Figure 1.1 is included as an overview of nisin biosynthesis. Nisin is 
encoded by nisA and is first translated into a prepeptide form of 57 amino acids. 
NisB is responsible for dehydration of serines and threonines that are found in 
the C terminal propeptide creating 2,3-didehydroalanine (Dha) or (Z)-2,3-
didehydrobutyrine (Dhb), respectively. NisC catalyzes formation of thioether 
linkages of cysteines to either Dha or Dhb creating lanthionine (Lan) or 
methyllanthionine (MeLan) residues, respectively [11-14].  NisBC has been 
shown to form a complex at the membrane and interacts with dedicated ABC 
transporter, NisT [15]. Once transported outside of the cell, the leader sequence 
of the prenisin is cleaved by a membrane bound subtilisin-like serine protease, 
NisP, removing 23 amino acids from the N-terminus [16]. Not all lan systems 
encode a dedicated serine protease. In the case of subtilin, three different serine 
proteases, not encoded by the locus, were identified that could process subtilin 
[17]. After modification and cleavage of the leader sequence, nisin is able to 
function as an antimicrobial and autoinducer for the upregulation of the nis locus 
by interaction with its cognate two component system, NisKR [18].  It was 
determined that the N-terminus of fully modified nisin was required for interaction 
with NisK to initiate a signaling cascade involving the phosphorylation of NisR 
[16, 18, 19]. Phosphorylated NisR is able to bind to the promoter regions of 
nisABTCIP, nisRK, and nisFEG [18, 20, 21] . There is a transcriptional attenuator 
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located between nisA and nisBTCIP which allows for higher expression of nisA 
but allows some read through of the downstream genes encoding the 
biosynthetic machinery under basal conditions [21]. This arrangement likely 
ensures the correct ratio of prenisin peptides to biosynthetic machinery enzymes. 
In addition to being upregulated in response to exogenous nisin, nisRK is also 
expressed constitutively so that the cell can immediately respond to nisin 
allowing for the rapid upregulation of the genes encoding immunity proteins, 
nisFEG and nisI [22]. An internal promoter upstream of nisI within the operon 
nisABTCIP was recently discovered which contributes to a basal level of 
immunity, further protecting nisin producing cells from nisin mediated inhibition 
[23]. 
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Figure 1.1 Biosynthesis of Nisin. A schematic of the nisin locus is shown 
above. An arrow above an open reading frame (ORF) depicts a promoter region. 
The promoters of nisI and nisRK are constitutively expressed. The other 
promoters are activated upon nisin exposure through NisRK signaling, creating a 
positive feedback loop as NisA is expressed. There is read-through allowing 
nisABTCIP to be transcribed on a single transcript. A transcriptional attenuator 
found in between nisA and nisBTCIP is present to allow for the correct 
stoichiometry of nisin to biosynthetic machinery. Nisin is first translated along 
with an N-terminal leader peptide that is needed for recognition by NisBC. After 
modification of NisBC, prenisin is secreted out of the cell by NisT. The leader 
peptide is cleaved by NisP resulting in the release of functional nisin which can 
either activate the nis locus in other nis positive strains or kill sensitive cells 
through lipid II binding and subsequent pore formation.   
  
Class II lantibiotics combine the action of dehydration and cyclization into 
a single modification enzyme called LanM [24].  Another difference between 
class I and class II lantibiotics is the N-terminal cleavage event. Instead of the 
cleavage occurring through an outer membrane protease, in class II lantibiotics 
the dedicated ABC transporter, LanT carries out the cleavage. LanT contains an 
N-terminal peptidase domain that recognizes a conserved cleavage motif ending 
in double glycine, GA, or GS sequence. This sequence is cleaved concomitantly 
with secretion releasing the mature peptide [25, 26]. In the case of mersacidin, a 
class II lantibiotic produced by Bacillus sp., it was found that  the regulation of 
mersacidin locus was under the control of a single response regulator, 
MrsR1[27]. Immunity to mersacidin was found to be under the control of the two 
component system MrsR2/K2 [27]. Although functional mersacidin is needed to 
induce expression of mrsA, it is unclear how MrsR1 is activated because it does 
not rely on MrsK2-dependent phosphorylation. This suggests that there might 
another histidine kinase not encoded by the locus that interacts with mersacidin 
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[27]. Two-peptide lantibiotics are members of the class II lantibiotics but their loci 
encode two separate LanM proteins that each modifies its own specific peptide 
[28, 29].  Two-peptide lantibiotics work synergistically to achieve an antimicrobial 
effect [30]. 
 Class III lantibiotics, unlike class I and II, do not have antibacterial activity 
and will not be discussed further. 
 While the four different classes of lantibiotic synthetases create either Lan, 
MeLan, or other Lab structures, many lantibiotics contain alternative 
modifications that are catalyzed by other enzymes. Some of the structures 
include S-aminovinyl-D-cysteine (AviCys) or S-aminovinyl-3-methyl-D-cysteine 
(AviMeCys) which can be found on the lantibiotics epidermin and mersacidin, 
respectively, and are a result of either EpiD or MrsD catalysis, respectively [31-
33]. Lantibiotics containing AviCys or AviMeCys have been found to be required 
for antimicrobial activity [34, 35]. Other modifications include the creation of a 
lysinoalanine bridge and a hydroxy-aspartate that are both found in the lantibiotic 
cinnamycin and duramycin [36, 37]. Formation of lysinoalanine and hydroxyl-
aspartate was attributed to the action of Cinorf7 and CinX in cinnamycin [36]. 
Interestingly, the hydroxyl-aspartate plays a role in cinnamycin’s ability to bind 
phosphatidylethanolamine (PE), which is different from the typical target, lipid II 
[38, 39]. Binding of PE prevents activation of phospholipase A2 that can lead to 
immunomodulatory effects on eukaryotic cells [40]. Duramycin, a lantibiotic that 
is structurally similar to cinnamycin, also has the same mechanism of action and 
is currently in phase II clinical trials for treatment of cystic fibrosis (CF) because it 
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was able to improve mucus clearance in CF patients. The mechanism of action 
likely affects membrane permeability of epithelial cells lining the airways that 
increases efflux of chloride ions, and reverses the defect in CF. [41-43]. 
1.3.2 Structure-Function Relationships  
 Lantibiotics are capable of inhibiting sensitive strains at nanomolar 
concentrations and this has been attributed to the lantibiotic’s mechanism of 
action . Nisin, which is part of the type-A(I) classification class of lantibiotics  
based on structure, is cationic and linear [44]. It has a total of five rings, three 
located on the N-terminus named A-C, and two more rings on the C-terminus 
named D-E (Fig.1.2). The two domains are separated by a flexible hinge region. 
Rings A and B of nisin are able to bind to the pyrophosphate of lipid II, which 
differs from the binding site of vancomycin [45, 46]. Deletion of the N-terminal 
rings or even changing the Lan to MeLan in ring A is sufficient to abrogate lipid II 
binding . Lipid II serves an important role in transporting cell wall precursors from 
the cytoplasm to the peptidoglycan layer. Lipid II is made in limited amounts and 
therefore, binding of nisin sequesters lipid II and cell wall synthesis is arrested. In 
addition to sequestering lipid II, nisin through its flexible hinge is able to insert its 
C-terminus into the membrane forming pores, which depolarizes the membrane 
potential leading to rapid cell lysis [47]. Decreasing the length of the hinge region 
in nisin from three amino acids to one was sufficient to abrogate its ability to form 
pores but lipid II binding was unaffected [48]. However, random mutagenesis 
yielding smaller sized amino acids such as alanine in the hinge region could 
enhance antimicrobial effect of either nisin A or nisin Z, presumably by increasing 
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accessibility of the C-terminus to the membrane and decreasing steric hindrance 
[49, 50]. Because of nisin’s dual mechanism of action, resistance to nisin is more 
difficult to acquire and has been used by the food industry for over 50 years.
 
Figure 1.2. Structure of Nisin. Nisin is a linear, cationic lantibiotic peptide. 
Functional nisin is 34 amino acids in length. Rings A-E are labeled in the above 
figure. Rings A and B are involved in lipid II binding and rings D and E are 
involved in pore formation. The hinge region is located from amino acid 20-22. 
Dehydroalanine and dehydrobutyrine are represented by the symbol Dha and 
Dhb,respectively, and are depicted in blue circles. Lanthionine (Ala-S-Ala) and 
methylanthionine (Abu-S-Ala) rings are represented in blue. 
  
Mersacidin, a type-B lantibiotic, is globular in shape consisting of four 
rings (A-D) and does not have a net charge [35, 51]. Mersacidin is able to bind 
lipid II via its ring C which is conserved in other mersacidin like lantibiotics but 
does not form pores like nisin and other flexible, cationic lantibiotics, most likely 
because it does not have a hinge region connecting a positively charged C-
terminus [52-54]. Through site directed mutagenesis, it was found that 
replacement of threonine residues involved in ring formation with serines in 
mersacidin abrogated lantibiotic production either because it cannot be properly 
modified or processed or because the resulting structure could not function as an 
autoinducer [55]. It was also found that the structure of ring B in mersacidin was 
most important for activity as insertions and deletions were not tolerated yet 
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amino acid substitutions could be made [55]. Overall, Appleyard et al. concluded 
that predictions of the activity of lantibiotics based on amino acid changes are 
hard to generalize [55]. 
 Whereas the lantibiotics of structure class A and B have been single 
peptide lantibiotics, there are cases of multi-peptide lantibiotics. Two peptide 
lantibiotics work synergistically to bring about antimicrobial activity, which 
includes binding to lipid II and formation of pores in most cases [56]. The two 
peptides (Lanα and Lanβ) tend to have very limited sequence identity and each 
peptide undergoes modification by a specific LanM protein encoded by lanM1 
and lanM2. After modification, the structures of Lanα and Lanβ are different [28, 
57]. Lanα tends to have a globular structure similar to mersacidin while lanβ is 
flexible and linear [30, 58]. It was shown in the case of lacticin 3147 that Ltnα 
binds to lipid II, which then recruits Ltnβ causing pore formation [30].  
Enterococcal cytolysins represent a unique approach to lantibiotic- 
mediated inhibition that includes the ability to sense the presence of sensitive 
cells. A unique property of cytolysin is that it is able to inhibit both eukaryotic and 
prokaryotic cells. Unlike other examples of two peptide lantibiotics, cytolysin, has 
only one modification enzyme that modifies both CylLL and CylLS [59, 60]. 
Interestingly, after a secondary cleavage event by CylA, the two peptides, CylLL″ 
and CylLS″ , play different roles [60, 61] . In the absence of target cells, CylLL″ 
and CylLS″ form an inactive complex and cytolysin expression is not upregulated 
in Enterococcus faecalis [62]. However, in the presence of eukaryotic cells, 
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CylLL″ has a higher affinity for binding to eukaryotic membranes, freeing up 
CylLS″ which then is able to relieve derepression of the cytolysin locus [62]. 
1.3.3 Mechanism of Self-Immunity 
 In addition to encoding the genes for the structural peptide, a lantibiotic 
producing strain must also express genes required for protection against the 
effect of its own lantibiotic. Two mechanisms of immunity exist in most lan 
systems encoded by the lanFEG and lanI genes.  The systems that protect nisin 
producing strains from their own peptide have been best studied and some 
version of these strategies are used by all previously reported lantibiotic systems.   
 NisFEG is an immunity ABC transporter that confers protection against 
nisin [63]. NisF is the nucleotide binding domain (NBD) of the ABC transporter 
that provides energy to the transporter by binding and hydrolyzing ATP as it 
contains the characteristic motifs found in other ATPases such as Walker A, 
Walker B, E-loop, and the H-loop as well as the C- and D-loops that are 
specifically found in some ABC transporters [64-67]. This E-loop was found to be 
important for immunity as mutating this glutamic acid residue resulted in little to 
no immunity [67]. This E-loop may be important in communication between NisF 
and the transmembrane domains (TMDs), NisE and NisG, to activate transport;  
the Q-loop was found to have this role in non-immunity transporters [67, 68]. 
NisE and NisG make up the heterodimer that forms the permease component of 
the transporter. Deletion of any single component of the ABC transporter disrupts 
immunity [63]. NisFEG is able to export nisin from the membrane into the 
environment without altering or destroying the peptide. 
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 NisI is a two domain protein consisting of 245 amino acid residues that is 
lipid anchored at its N-terminus to the outside of the cell membrane [69]. Some 
NisI escapes membrane attachment and is secreted into the environment [70]. 
Secreted NisI is able to protect the cell from nisin mediated killing by binding to 
nisin without modifying or degrading the molecule [22, 70-73]. The C-terminus of 
NisI seems to play a role in the protective effect of NisI as it was shown that 
deleting up to 22 amino acids from the C-terminus decreased immunity and could 
not prevent nisin mediated pore formation [73, 74]. To verify that this phenotype 
was not attributed to an improper folding of NisI, a chimera immunity protein was 
created fusing the C-terminus of NisI to the N-terminus of a different lantibiotic 
immunity protein, SpaI, which confers protection against the lantibiotic subtilin. 
Although the structures of subtilin and nisin are very similar, the immunity 
proteins are very specific and SpaI does not protect against nisin. The chimera 
immunity protein with the C-terminus of NisI was found to protect against nisin 
[74]. This suggests that the C-terminus of NisI is able to inhibit pore formation 
mediated by nisin although the exact mechanism is unclear.  
Nisin binding directly to NisI is unlikely to represent the only mechanism 
for protection. It was recently found that when L. lactis was exposed to high 
concentrations of nisin that would saturate NisI binding, L. lactis was still 
protected from nisin-,mediated inhibition in a NisI dependent manner. AlKhatib et 
al. propose that the C-terminus of NisI might be able to bind to lipid II, preventing 
nisin from binding and inhibiting subsequent pore formation. Additionally, L. lactis 
expressing either NisI or NisI with the 22 amino acids deleted from the C-
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terminus important for binding to nisin, were shown to induce long chains of 
bacteria at high concentrations of nisin [73]. As nisin concentrations decrease, 
the phenotype was restored to wildtype (WT). Although the exact mechanism of 
how long chain formation impacts immunity or how NisI induces this 
morphological change is unknown. 
 NisI and NisFEG are believed to function cooperatively to provide full 
immunity. A strain containing a deletion of either immunity protein was shown to 
have only 10-30% of full immunity.  It appears that  NisI contributes quantitatively 
more to immunity than NisFEG  [72, 75]. Although some lantibiotics like the 
mersacidin locus only encode MrsFGE, it is believed that lantibiotics capable of 
binding to lipid II and forming pores require the actions of both immunity proteins 
[27, 76]. 
 
1.4 Streptococcus pneumoniae 
 S. pneumoniae, a Gram-positive bacteria, is a common colonizer of the 
human nasopharynx [77]. It has been shown that colonization by pneumococcus 
happens early in life and often with more than one capsule type or serotype [78]. 
By adulthood, carriage decreases, therefore, young children represent the major 
pneumococcal reservoir [79]. Although, pneumococcus is a commensal, it has 
the ability to transition to a pathogenic form. Once it gains access to other sites in 
the body, pneumococcus is able to cause a variety of diseases ranging from otitis 
media to more severe, invasive diseases such as pneumonia, meningitis, and 
bacteremia [80]. Worldwide it has been estimated that about 1.6 million people 
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die from pneumococcal infections [81]. In the United States, about 4 million 
people have a pneumococcal related illness each year and 22,000 of those 
infections result in death [82]. Of the 4 million, 1.2 million of those cases are 
caused by drug resistant pneumococcus [82]. 
Currently, there are vaccines to protect against specific serotypes of 
pneumococcus that are known to cause severe disease. Although these 
vaccines have proven effective at preventing pneumococcal disease in 
susceptible populations, the use of these vaccines has altered the composition of 
colonizing pneumococcal populations to include less common serotypes.  Many 
of these replacement serotypes are capable of causing severe infections [83, 84]. 
The reason for this is attributed to the ability of pneumococcus to evade the 
immune system by undergoing capsule switching along with the high pre-existing 
diversity in capsule type [85].  
Antibiotics can be used to treat pneumococcal infections.  However, the 
continued use of penicillin, which was historically the first drug of choice, resulted 
in the rapid emergence of penicillin resistant strains [86]. Although the 
introduction of vaccines has eliminated certain antibiotic resistant serotypes, 
antibiotic resistance continues to be a problem and further complicates treatment 
[87-89]. 
Studying pneumococcal competition is important not only for the 
identification of bacteriocins which may be used as a future therapeutic, but also 
for identifying factors that are important for successful colonization. By knowing 
what factors are important for colonization, specifically through competitive 
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interactions mediated by the secretion of bacteriocins, we can predict which 
pneumococcal strain will be gain prominence in a population and target those 
specific strains.  The following sections will examine what is known about 
pneumococcal bacteriocins, especially lantibiotics. 
1.4.1. Pneumococcal Bacteriocins 
 S. pneumoniae is known to secrete bacteriocins that mediate competition 
in the human nasopharynx [90]. The bacteriocin- like peptide (blp) locus is found 
in all sequenced pneumococcal strains and contains not only the genes encoding 
the bacteriocins but also genes required for transport, processing, regulation, and 
immunity [91, 92]. The Blp bacteriocins are small, unmodified peptides that 
contain an N-terminal leader peptide that directs the Blp bacteriocins to BlpAB. 
BlpAB is an ABC transporter complex that contains a peptidase domain that 
cleaves off the leader peptide upon secretion [93]. After cleavage and secretion, 
the Blp bacteriocins are functional and can inhibit strains that lack the 
corresponding immunity proteins [94]. Expression of the blp-associated genes is 
upregulated when the signaling pheromone, encoded by blpC interacts with the 
two component system, BlpRH [92]. Expression of blpC itself is also upregulated 
in response to BlpC signaling, which creates a positive feedback loop [92].  
Another pneumococcal bacteriocin is the competence induced bacteriocin 
(Cib). Competence is the ability of bacteria to uptake exogenous DNA and 
integrate into the genome. Pneumococcal competence is controlled by a 
signaling pheromone named competence stimulating peptide (CSP) which 
interacts with its cognate histidine kinase, ComD, to upregulate genes necessary 
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for competence development [95]  The genes upregulated through CSP-
mediated signaling include,the two peptide bacteriocin, CibAB. CibAB has been 
shown to play a role in competence-mediated fratricide, resulting in allolysis of 
noncompetent cells [96]. 
Several putative lantibiotic loci have been identified in pneumococcal 
genomes although no antimicrobial activity has been attributed to these clusters 
[97-100]. Some loci have been shown to have antimicrobial function when 
expressed under  heterologous conditions, for example, heterologous expression 
of a two-peptide lantibiotic, PneA1 and PneA2, derived from a sequence found in 
the pneumococcal strain, D39, was able to undergo modification using the nisin 
biosynthetic enzymes, NisBC [101]. Modification by NisBC was successful upon 
replacement of PneA’s leader peptide sequence with that of nisin [101]. 
However, the two peptides did not act synergistically when combined and the 
resultant peptide was only found to have antimicrobial activity against 
Microcococcus flavus [101]. The modifications generated by NisBC may not 
reflect the true structure of PneA. This is an interesting method to study the 
function of  lantibiotics that lack antimicrobial activity in their native backgrounds 
[101]. Recently, the same locus was found to be under the control of a quorum 
sensing system identified as TprA/PhrA and was upregulated in the presence of 
galactose but repressed under high glucose growth conditions [100]. 
Interestingly, the nasopharynx is high in galactose but low in glucose suggesting 
that the locus may be active on this surface. It is not clear whether the peptides 
that may be produced by this locus under high galactose conditions have 
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inhibitory activity as the authors in this study did not demonstrate any 
antimicrobial function [100]  
Some lantibiotic loci that have been identified in pneumococcus have 
been located on integrative and conjugative elements (ICE). ICE are acquired by 
pneumococcal strains because they harbor genes with beneficial properties such 
as antibiotic resistance genes [102]. Pneumococcal strain ATCC700669 was 
found to contain a lantibiotic locus on an ICE termed ICESp23FST81 [97]. In 
addition to the lantibiotic locus, other cargo genes that code for antibiotic 
resistance and DNA repair enzymes were found which might explain the 
prevalence of this ICE in pneumococcal genomes [97]. Notably, pneumococcal 
strain ATCC700669 is a member of the serotype 23F sequence type 81 lineage, 
a pandemic strain, suggesting that having an ICESp23FST81 may have 
contributed to its fitness and transmission, although antimicrobial activity was not 
observed from its lantibiotic locus [97].  
To summarize, lantibiotic loci in pneumococcus have been identified 
although antimicrobial activity has not been described for any of them. Two 
lantibiotic loci located on ICE have been disseminated in the pneumococcal 
population indicating these lantibiotic loci may be under positive selective 
pressures. The contribution of these lantibiotic loci to competitive dynamics and 
colonization is unknown but may represent an additional strategy to compete with 
other bacteria in the nasopharynx. My dissertation research examines the first 
functional lantibiotic locus expressed in a clinical isolate of Streptococcus 
pneumoniae, P174. This locus encodes the named lantibiotic, pneumolancidin 
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(pld) that demonstrates broad-spectrum antimicrobial activity. Understanding 
lantibiotic structure, function and regulation and will provide further insight into 
how bacterial metabolites can shape a host-associated microbial community. 
  
1.6  Outline of the Thesis 
 The central goal of this thesis is to characterize the pneumolancidin (pld) 
locus in Streptococcus pneumoniae. The pld locus is noteworthy not only 
because of the broad spectrum of inhibition associated with it, but also the 
presence of four highly homologous lantibiotic peptides. Lantibiotic peptides are 
known to have two roles, acting as both a growth inhibitor for some cells and an 
auto-inducer.  In Chapter I, I dissect the role of each Pld peptide as it relates to 
growth inhibition, locus upregulation, and immunity using a genetic approach. I 
also characterized the role of each gene in the pld locus. Additionally, I 
uncovered the reason why some strains that possess the pld locus are 
nonfunctional. Finally, I examined the biological significance of having a 
functional pld locus using a staggered colonization mouse model. In Chapter II, a 
biochemical approach was employed to assess the role of purified Pld peptides. 
PldA1 and PldA3 were successfully purified and their bioactivities were 
determined. The complete structural elucidation of PldA1 and PldA3 was also 
achieved. In Chapter IV, I discuss the significance of my thesis research, and the 
future directions needed to address near-term and longer-term questions. 
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CHAPTER II 
 
CHARACTERIZATION OF A MULTI-PEPTIDE LANTIBIOTIC LOCUS IN 
STREPTOCOCCUS PNEUMONIAE 
 
N Maricic, ES Anderson, AE Opipari, EA Yu, and S Dawid, mBio 2016 
7(1):e01656-15 
Abstract 
Bacterial communities are established through a combination of cooperative and 
antagonistic interactions between the inhabitants.  Competitive interactions often 
involve the production of antimicrobial substances including bacteriocins, which 
are small antimicrobial peptides that target other community members. Despite 
the nearly ubiquitous presence of bacteriocin encoding loci, antimicrobial activity 
has only been attributed to a small fraction of gene clusters. In this study, we 
characterize a novel locus in the pathogen Streptococcus pneumoniae that 
drives the production of a bacteriocin called pneumolancidin (pld) with broad 
antimicrobial activity. The locus encodes an unusual tandem array of four 
inhibitory peptides, three of which are absolutely required for antibacterial 
activity. The three peptide sequences are similar, but appear to play distinct roles 
in regulation and inhibition.  A modification enzyme typically found in loci 
encoding a class of highly modified bacteriocins called lantibiotics was required 
for inhibitory activity. The production of pneumolancidin is controlled by a two 
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component regulatory system that is activated by the accumulation of modified 
peptides.  The locus is located on a mobile element that has been found in many 
pneumococcal lineages although not all elements carry the pld genes.  
Intriguingly, a minimal region encoding only the genes required for 
pneumolancidin immunity was found in several Streptococcus mitis strains.  The 
pneumolancidin producing strain can inhibit nearly all pneumococci tested to date 
and provided a competitive advantage in vivo.  These peptides not only represent 
a unique strategy for bacterial competition but are also an important a resource 
to guide the development of new antimicrobials.   
 
2.1  Introduction 
Streptococcus pneumoniae is a common colonizer of the human nasopharynx, a 
highly diverse polymicrobial environment [103-105]. Bacterial competition 
between members of the microbiome is often mediated by antimicrobial peptides 
called bacteriocins.  In pneumococci, competition is enhanced in strains with a 
functional bacteriocin locus during nasal colonization of the mouse [90]. 
Bacteriocin production in pneumococcus is controlled by the blp locus, which has 
been identified in all sequenced strains [90, 93, 106]. Most pneumococcal 
genomes also contain the cib locus which encodes a highly conserved two 
peptide bacteriocin, CibAB, that has been shown to play a partial role in 
competence mediated fratricide resulting in allolysis of noncompetent cells [96]. 
Both the blp and cib loci are predicted to encode Class II, or unmodified peptide 
bacteriocins. 
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Lantibiotics are a specific class of bacteriocins that are characterized by their 
extensive posttranslational modifications.  Secretion of functional lantibiotics has 
not been described in pneumococcus. Precursor lantibiotic peptides are modified 
intracellularly by one or more enzymes encoded by genes contained within the 
specific lan locus. The most common modification involves the dehydration of 
serines and threonines and through a thioether linkage, cyclization of the 
dehydrated amino acids to cysteines creating either lanthionine or 
methyllanthionine, respectively [11-14, 24]. Following modification, the pre-
lantibiotic is transported out of the cell by a dedicated ABC transporter that 
recognizes a conserved signal sequence [14]. The signal peptide is either 
cleaved concomitantly with secretion by the transporter, or by an alternative 
protease [16].  Cleavage of the signal sequence renders the lantibiotic active and 
able to exert an antimicrobial effect on susceptible cells by either binding to lipid 
II and blocking cell wall synthesis and/or forming pores [107]. This dual 
mechanism of action can be combined in a single lantibiotic peptide or split 
among two peptides. Modification of a two-peptide lantibiotic typically requires 
two LanM, each one specific for one peptide [28, 57, 108-110]. Self-immunity to 
lantibiotics can occur through expression of a lipoprotein that is thought to 
competitively bind to the lantibiotic or through production of an efflux ABC 
transporter. Some loci encode for both immunity strategies, in these cases partial 
immunity defects are noted when one gene is deleted. In most cases, the 
lantibiotics also function as signaling peptides and interact with a cognate 
histidine kinase, LanK. Binding of the lantibiotic to the histidine kinase results in 
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upregulation of the locus via a two component regulatory cascade [18, 111, 112]. 
Some potential lantibiotic encoding clusters have been described in 
pneumococcus, however, no activity has been attributed to these loci. Some 
members of the pandemic pneumococcal strain, Spain23F sequence type 81 
lineage, that at one point was found to be responsible for 40% of pneumococcal 
disease in America, carry a locus that appears to have all required elements for 
lantibiotic expression, but no inhibitory activity has been detected in strains 
carrying this locus [97, 98]. In this study, we report the identification of the first 
functional lantibiotic locus in pneumococcus. The activity derived from this locus 
inhibits a significant number of pneumococci and other Gram-positive pathogens.  
It requires the concerted action of three similar but distinct structural peptides, all 
of which appear to be modified by the same LanM enzyme. To our knowledge, 
the requirement for three homologous peptides for full inhibitory activity of a 
lantibiotic has not been described previously and represents a unique approach 
to bacterial antagonism.   
2.2  Results 
2.2.1 Identification of a functional lantibiotic locus in P174 
During previous work on the blp locus, we noted that an invasive serotype 
23F isolate derived from a patient in South Africa had significant antibacterial 
activity against  all but one pneumococcal isolate despite containing an 
inactivating mutation in the blp bacteriocin locus [93]. Deletion of the upstream 
regulator of the cib or blp bacteriocins (comDE or blpC, respectively) did not 
abrogate inhibitory activity suggesting that the inhibitory activity was derived from 
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a previously undescribed locus (Fig. 2.1A). Transposon mutagenesis localized 
the activity to a locus predicted to encode a series of lantibiotic peptides.
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Fig.2.1. Inhibitory activity and genetic structure of the pld lantibiotic locus. 
A) Overlay assays were performed using either P174 wildtype or deletion 
mutants of either upstream regulators of the blp or cib locus or a deletion of the 
pldM gene that was identified in the transposon mutagenesis screen. A TIGR4 
strain was used as the overlay strain. B) The pld locus of P174 and the 
corresponding locus of S. mitis, and S. pneumoniae ATCC700669 are shown 
above. The percentage of amino acid identity between the predicted proteins 
found in S. mitis B6 and P174 homologues is noted above the B6 ORFs. 
Presumed functional designations are indicated by the color of the ORF. Regions 
of DNA homology between sequences are shown as grey background. C) Amino 
acid alignment demonstrating the homology between predicted structural 
proteins PldA1-4. The proposed signal peptide sequence cleavage point is 
shown with a vertical arrow. Shared amino acid residues in the functional peptide 
are highlighted in yellow. Amino acid residues in red indicate sites of possible 
modification catalyzed by PldM.  D) Deletions of various genes in the pld locus of 
P174 were constructed and assayed for inhibitory and signaling activity as well 
as immunity to WT lantibiotic.  Inhibition and signal secretion were tested by 
stabbing the strain of interest and overlaying with the sensitive indicator strain, 
TIGR4 or the reporter strain P174 pldM-lacZ, respectively. The chromogenic 
substrate, X-gal was included in the overlay mixture for signaling assay. 
Immunity was determined by stabbing P174 and overlaying with each of the 
deletion mutants. 
 
A schematic of the locus is shown in Fig. 2.1B. We chose to designate this 
lantibiotic locus as pneumolancidin and the corresponding genes abbreviated to 
pld per the standards of nomenclature for lantibiotics. A  nucleotide BLASTn of 
the pld locus found in P174 demonstrated that a homologous gene cluster is 
found  in a pneumococcal strain designated PN1, isolated from Papua New 
Guinea in the 1970’s [99]. The locus encodes two ABC transporters, the 5’-most 
genes consist of two ORFs, pldFE that encode an ATP binding protein and a 
permease, respectively. These genes share 99% amino acid identity with an 
ABC transporter identified in PN1 and 97% similarity with a transporter encoded 
in the Streptococcus mitis B6 genome. Based on conserved domains PldF 
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serves as the nucleotide binding domain of an immunity ABC transporter. 
Although it does not contain a typical E-loop which is conserved in all LanF 
proteins of immunity ABC transporters, we chose to name the genes pldFE 
based on the location of these genes in the locus, homology, and likely immunity 
function [67]. The proteins also share homology to bacitracin ABC transporters 
found in a number of streptococcal species that provide resistance to bacitracin 
and can provide cross resistance to heterologous lantibiotics such as nisin and 
gallidermin  [113-115]. A second ABC transporter, pldT, was identified in the 3’ 
region of the locus. The second ABC transporter shared 31% identity at the 
amino acid level to the mersacidin ABC transporter, MrsT, in Bacillus sp. and 
contains conserved domains involved in lantibiotic export and cleavage. The only 
modification enzyme found in the locus is encoded by the pldM gene. PldM is a 
member of the LanM family of modification enzymes. The pld locus contains 
coding sequences for a two component regulatory system, pldKR, which is 
homologous to genes found in the S. mitis B6 strain. Homologs of S. mitis B6 
pldKR are adjacent to the immunity pldFE homologs, but the surrounding region 
lacks the remainder of the pneumococcal pld locus (Fig. 2.1B). Flanking either 
end of the pld locus in P174 are regions of significant homology to the ICE 
element found in the S. pneumoniae strain ATCC 700669. This strain has a 
lantibiotic locus in the precise location of the pld locus although the genes in the 
two loci share no homology (Fig 2.1B).  
A region encoding the putative structural proteins was identified upstream 
of pldFE. A tandem array of four possible ORFs were identified (pldA1-4), each 
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encoding a peptide with a  signal sequence followed by a sequence with a large 
number of serines, threonines and cysteines typically found in lantibiotic 
peptides. The predicted Pld peptides do not share homology to known lantibiotic 
peptides. The four ORFs are homologous to each other and the N-terminal 
leader sequence of each peptide is followed by a double glycine, GA, GS, or 
double alanine motif suggesting the point of peptidase cleavage. The active 
peptides of PldA1 and PldA2  would be predicted to differ by only two amino 
acids (Fig. 2.1C). 
2.2.2 Identification of the genes required for lantibiotic activity and immunity. 
To determine the role of each gene in the pld locus of P174, individual deletions 
were constructed and assayed for inhibition and immunity to the P174 secreted 
lantibiotic. Deletions in pldM, pldT and pldK, encoding the modification enzyme, 
lantibiotic transporter, and histidine kinase, respectively all resulted in loss of 
inhibition (Fig. 2.1D). When tested for immunity, the pldM and pldT deletion 
strains retained immunity to P174 while the pldK mutant lost immunity confirming 
the requirement for the regulatory proteins for activation of lantibiotic immunity. 
To determine the role of pldFE, an inframe, unmarked mutation of both genes 
was introduced into P174.  This mutant, P174 ∆pldFE, lacked inhibition in overlay 
assays and was sensitive to WT secreted lantibiotic peptide, suggesting that this 
ABC transporter is required to initiate immunity or is directly involved in protection 
from its own lantibiotic (Fig. 2.1D).  As expected, Pld peptides are required for 
inhibition but not for immunity since a strain carrying a deletion of all 4 peptides 
had loss of inhibition but retained immunity (Fig. 2.1D). P174 displays an 
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interesting self-inhibitory phenotype in which the formation of a halo of decreased 
density of growth can be seen when P174 is plated against itself, suggesting that 
there is a lapse in the development of immunity in this assay which allows for 
some degree of self-inhibition in the presence of functional lantibiotic peptides. 
This phenomenon is also seen when P174 is grown as a single strain lawn where 
it is noted to form occasional plaque-like structures that are characterized by 
areas of partial clearing.  Although the mechanism for the development of 
plaques is unknown, we hypothesize that these are areas in which the pld locus 
is spontaneously activated in a portion of the population, resulting in the inhibition 
of any neighboring cells that are delayed in their production of immunity.   
2.2.3 Modified lantibiotic peptides are required for activation of the locus. 
In addition to their inhibitory activity, lantibiotic peptides also often serve as 
inducers by interaction with the cognate histidine kinase leading to upregulation 
of the entire lan locus. Upregulation of the locus is dependent upon the 
concentration of the lantibiotic peptides. Similar to other lantibiotic loci, we found 
that the Pld peptides are required for activation of transcription of the pld locus.   
We compared the activation of a pld reporter construct to the signal secreted by 
P174 in the P174 and P174 ΔpldA1-4 background (Fig. A1). The reporter strain 
in the wildtype background produced a large zone of signaling when plated over 
a peptide secreting strain, while only a small zone was seen when the reporter in 
the P174∆pldA1-4 background was tested.  Because the stabbed strain secretes 
the same amount of peptide in each overlay, this result suggests that 
propagation of the signal within the overlay results in a larger activation zone and 
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further suggests that this propagation requires the lantibiotic peptides.   Similarly, 
P174 ΔpldA1-4 does not secrete a signal that can stimulate the reporter strain 
P174 pldM-lacZ, further supporting the role of Pld peptides as inducers of the pld 
locus (Fig. 2.1D). To determine if the Pld peptides need to be modified and 
secreted to act as inducers, P174ΔpldM or P174ΔpldT were stabbed and 
overlaid with the WT reporter (Fig. 2.1D). Stimulation of the pld locus was not 
seen in either overlay confirming that the induction signal of the locus is an 
extracellular, modified peptide. As expected, the P174ΔpldK strain, which lacks 
the histidine kinase regulator was not able to secrete a signal, consistent with a 
loss of both inhibition and immunity in this strain (Fig. 2.1D). Surprisingly, the 
strain carrying the unmarked pldFE mutation, missing the genes that are 
proposed to play a role in immunity, also did not secrete a signal despite 
retaining the genes encoding the peptides and the regulatory, modification and 
secretion proteins (Fig. 2.1D). This may be due to development of a 
compensatory mutation that prevents the activation of the locus in the setting of 
reduced immunity, or because the immunity transporter plays an undefined role 
in regulation.  We attempted to evaluate the kinetics of activation of the locus in 
broth culture using the pldM-lacZ reporter strain, but this strain failed to show any 
induction of the locus during growth in broth, presumably because the 
concentration of peptides never reaches the level required to support activation 
of the locus under these conditions (data not shown). 
Given the unusual presence of four homologous but not identical putative 
functional peptides, we wanted to determine the function of each peptide 
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individually in inhibition and signaling. Individual, in frame, unmarked peptide 
deletions were tested for inhibition, immunity and evidence of signal secretion 
(Fig. 2.2). P174 lacking pldA1, pldA2, or pldA3 had identical phenotypes in that 
all three deletion strains had a loss of inhibitory activity and signal secretion (Fig. 
2.2A), suggesting that all three peptides are required for activation of the locus.  
These strains had nearly wildtype levels of immunity to P174, with only a small 
zone of clearing that most likely represents some degree of delayed production 
of immunity.  P174 ∆pldA4 was fully inhibitory and secreted a signal that was 
indistinguishable from P174 suggesting that this gene is dispensable for inhibition 
(Fig. 2.2A).  
 
Figure 2.2. Deletion of the lantibiotic peptide in either P174 or the 
hyperinducible P174act background. In frame, unmarked peptide deletion 
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mutants were constructed and assayed for inhibitory and signaling activity as well 
as immunity to WT lantibiotic.  Evidence of inhibition and signal secretion were 
tested by stabbing the strain of interest and overlaying with the sensitive indicator 
strain, TIGR4, or the reporter strain P174 pldM-lacZ, respectively. Immunity was 
determined by stabbing P174 and overlaying with each of the deletion mutants. 
Peptide deletion mutants that were made in either the P174 background (A) or 
the P174act background (B). C) Phenotypic complementation was assayed using 
P174act ∆pldA3 and P174act ∆pldA1. Both strains were stabbed progressively 
more closely to each other and the plate subsequently overlaid with TIGR4. 
Pictures were taken at a higher magnification (2x) than other overlays to better 
appreciate the inhibitory effect.  
 
2.2.4 Hyperinducible strain of P174 has a decreased threshold for locus 
activation. 
Surprisingly, we found that certain isolates derived from allelic exchange of the 
counter selectable Janus cassette with a cloned copy of the peptide region that 
was being used for constructing peptide deletions, had an altered lantibiotic 
production phenotype which we have designated as P174act. When the pldM 
reporter plasmid was integrated into this strain, it exhibited evidence of greater 
pldM transcription in overlay assays when stimulated with P174 and produced a 
large number of plaque-like formations in the overlay lawn when compared with 
the reporter in the wildtype background (Fig.2.3A). When P174act was stabbed 
into plates, there was no significant difference in inhibition or signaling compared 
with the wildtype strain (Fig. 2.2A & B). To determine the mutation responsible for 
the hyperinducible phenotype of P174act, we sequenced the entire fragment that 
was used for allelic exchange. Sequencing revealed a single base pair mutation 
presumably attributable to a PCR error that was located in the intergenic region 
between pldA4 and pldFE (Fig. 2.3B). The mutation was found in the cloned 
fragment used for transformation and, using linkage analysis on transformants 
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that resulted from allelic exchange with the plasmid carrying the mutation, was 
absolutely linked to the hyperinducible phenotype (data not shown). The mutation 
resulted in a change of a thymidine to a cytosine at the first T of the proposed 
TATA box preceding pldFE (Fig. 2.3B). Because this mutation was in an 
intergenic region downstream of the peptide ORFs, we reasoned that this single 
base pair change was affecting transcription of key genes in the locus by either 
disrupting a transcriptional attenuator (allowing for increased read-through) or 
affecting a promoter element (in particular by altering RNA polymerase binding at 
the -10 region) either of which might result in changes in downstream gene 
expression. DNA analysis failed to demonstrate any sequences likely to form a 
stem-loop typical of a transcriptional attenuator. To further examine this, a 4bp 
deletion that included the site of the mutation was constructed in the P174 and 
both the inhibition and immunity phenotype of the resulting strain was assessed 
(Fig.2.3C). The strain carrying this deletion lost both inhibition and immunity 
making the presence of a transcriptional terminator at this site unlikely and 
suggesting that the mutation that results in the act phenotype was affecting the 
activity of a promoter element preceding pldEF.  
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Figure 2.3. A hyperinducible strain contains a mutation that is affecting the 
promoter upstream of pldFE. A) Response to exogenous peptides was tested 
in either P174 pldM-lacZ or P174act pldM-lacZ. P174 was stabbed multiple times 
into TS plates and overlaid with either reporter. B) Location of the single base 
pair mutation resulting in the hyperinducible phenotype in the intergenic region 
between pldA4 and pldFE. The site of the mutation is marked by an asterisk. The 
4 bp region shown in red was deleted in strain P174Δ4bp. The proposed TATA 
box preceding the pldF ORF is underlined. The distance to the start codon of 
pldF as denoted by N. C) Overlay assays assessing inhibition and immunity 
phenotype of the 4bp deletion that included the site of the activating mutation. 
For inhibition, the P174Δ4bp strain was stabbed and overlaid with TIGR4. For 
immunity, P174 was stabbed onto a TS plate and overlaid with the P174Δ4bp 
strain.  
 
2.2.5 Genes involved in immunity, regulation and peptide modification are not 
part of an operon. 
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We attempted to determine the transcriptional units of the locus and to compare 
RNA levels in wildtype and hyperinducible backgrounds using both RT-PCR and 
northern blotting, however, transcripts could not be detected in broth grown 
organisms and RNA isolated from plate grown organisms was too degraded for 
use in RT experiments (data not shown). As an alternative approach to 
determining minimal transcriptional units and relative activity of various genes in 
the pld locus, we constructed three additional reporters in either the P174 or 
P174act background through plasmid integration in which the reporter gene lacZ 
was fused to the region upstream of either pldK ,pldFE, or pldA1. All constructed 
reporter strains were tested for inhibition and signal secretion. All of the fusion 
constructs retained the wildtype inhibitory phenotype (Fig.A2a) demonstrating 
that insertion of the reporter plasmid at either of these locations did not disrupt 
the function of the locus. Like the pldM reporter, the pldFE reporter demonstrated 
signal detection when overlayed over P174. The pldA1-lacZ fusion in either 
background was upregulated in response to exogenous peptides indicating that 
the peptides are autoregulated (Fig.A2a). Although the pldK reporter can secrete 
wildtype levels of peptide by signal secretion assay and inhibits the TIGR4 strain 
in overlay assays, this reporter in either P174 or P174act background was not 
activated by P174 when used in an overlay assays (Fig.A2b). This indicates that 
the genes involved in regulation are not inducible with exogenous peptides and 
that the pldFE, pldKR and pldM genes are all controlled by separate promoters 
since the peptide inducible promoters of pldFE and pldM flank either side of the 
non-induced pldFE genes (Fig. 2.1B). The lack of appreciable lacZ expression in 
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the pldKR reporter suggests that the regulatory genes are produced at very low 
levels and are not part of the positive feedback regulation in response to 
secreted peptides. In addition, the lack of appreciable activity of this reporter in 
the P174act background suggests that the alteration of the promoter in front of 
pldFE that is responsible for the hyperinducible phenotype does not appreciably 
alter expression of the downstream regulatory genes.   
2.2.6 The hyperinducible mutation functions only when directly upstream of 
pldFE. 
To better determine the role of the mutation in the hyperinducible phenotype, we 
created two additional reporter plasmid integrations into the promoter of pldF in 
which the P174act mutation was placed upstream of lacZ only or upstream of 
pldF only (Fig. 2.4A). The activity of these strains in reporter overlay assays was 
compared with the wildtype reporter strain, P174 pldF-lacZ by using cell free 
supernatant preparations of cultures of P174act to activate the locus (Fig. 2.4A). 
Only the reporter that had the mutation directly upstream of the pldF gene had 
the hyperinducible (multiple plaque forming) phenotype as seen with the multiple 
spots of lacZ expression (Fig.2.4A). When comparing the relative activity of the 
wildtype reporter strain with the strain containing the mutation only in front of 
lacZ, it appeared that the reporter with the mutation had relatively less induction 
suggesting that the mutation may decrease the activity of the pldF promoter 
(Fig.2.4A).   
To better understand the hyperinducible phenotype, we used cell free 
supernatant preparations of cultures of P174act as an inducer to measure β-
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galactosidase activity (Fig. 2.4B). Two fold dilutions of the cell free supernatant 
were used to induce the wildtype P174 pldF-lacZ reporter strain and the same 
reporter with the act mutation in front of lacZ (P174 PactpldF-lacZ) or in front of 
pldF (P174act P174pldF-lacZ). The P174act P174pldF-lacZ strain showed a clear 
dose response to increasing concentrations of supernatant (Fig 2.4B). P174 
pldF-lacZ or P174 P174actpldF-lacZ strains showed no appreciable activation of the 
locus (Fig 2.4B). These findings suggest that the act mutation results in a 
decreased threshold for signaling resulting in enhanced transcription of the locus 
even at low peptide concentrations and confirms our observations on plates that 
the mutation must lie directly 5’ to the start codon of pldF to demonstrate the 
hyperinducible phenotype.   
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Figure 2.4. Transcriptional Activity of pldF-lacZ fusion strains in either P174 
or P174act background. A) Schematics of the pldF-lacZ reporter strains are 
shown after plasmid integration. Dotted lines denote the plasmid-derived 
sequence; the lacZ gene is shown as a light blue arrow. An asterisk depicts the 
site of the act mutation. To the right of the corresponding schematic of the locus 
is the phenotype of each construct grown on TS plates containing X-gal in which 
5 µl of crude P174act derived supernatant was added to the center of a lawn for 
induction. Response to supernatants was evidenced by the blue halos. B) 
Transcriptional activity of the promoter driving lacZ was assessed in in broth 
grown organisms using strains P174, P174 pldF-lacZ, P174PactpldF-lacZ, and 
P174actP174pldF-lacZ. Two fold dilutions of crude P174act derived supernatant 
was added to the strains at an OD620 of 0.2 and induced for 1.5 hours.  Activity 
was determined by calculating Miller Units. To account for endogenous β-
galactosidase activity, wildtype P174 was included.  
 
2.2.7 Three distinct phenotypes for peptide found in the P174act background. 
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Given the decreased threshold for signaling in the hyperinducible 
background, the three unmarked peptide mutations that lacked inhibition in 
overlay assays in the wildtype background were moved into this background and 
assessed for secretion of signaling and inhibitory peptides (Fig. 2.2B). In this 
background, the three deletion strains had three distinct phenotypes in overlay 
assays. The pldA1 deletion in the P174act background retained signal secretion 
but lost inhibition. The strain carrying the pldA2 deletion was indistinguishable 
from the P174 wildtype strain. The P174act ∆pldA3 deletion strain had the most 
dramatic phenotype and lost all signal secretion and inhibition.  The inhibitory 
defect in the P174act∆pldA1 strain could be phenotypically complemented by 
placing an adjacent stab of the P174act∆pldA3 strain confirming the overall 
integrity of the locus in each deletion mutant (Fig. 2.2C). It is important to note 
here that the active peptide sequences of PldA1 and PldA2 only differ by two 
conserved amino acids. The difference in the phenotypes of the pldA1 and pldA2 
knockout in the P174 and P174act backgrounds suggest that both are required 
for signaling when thresholds are at wildtype levels, but PldA2 plays less of a role 
in inhibition than PldA1 when the signaling threshold is low.   
2.2.8 Broad spectrum of inhibitory activity derived from pld locus. 
P174 lantibiotic derived inhibitory activity was examined using a previously 
described collection of 50 pneumococcal isolates from South Africa and the 
alternative lantibiotic expressing ATCC 700669 [93]. Additionally, a selection of 
non-pneumococcal strains was tested for sensitivity to P174. Inhibitory activity 
was found against all but one of the pneumococcal strains as well as isolates of 
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Streptococcus oralis, Listeria monocytogenes, Streptococcus pyogenes, 
Streptococcus agalactiae, and Lactococcus lactis (Table 2.1). Further information 
on the pneumococcal and streptococcal strains tested can be seen in Table A1. 
Strains that were sensitive to P174 were also tested against P174 ∆pldK to 
confirm that activity was attributed to the pld locus. A single strain, P130 was the 
only pneumococcal isolate that had immunity when tested against P174 in the 
overlay assay. 
Table 2.1.  Spectrum of Inhibitory Activity for P174.  
Strain Inhibition by P174 
pld negative Streptococcus pneumoniae + (50/50) 
pld positive Streptococcus pneumoniae  + (4/5) 
Lactococcus lactis ATCC 14365 + 
Streptococcus pyogenes Clinical Isolates and Lab strains  + (12/12)¥ 
Listeria monocytogenes 10403S + 
Streptococcus agalactiae Clinical and Lab Strains  + ( 6/15)¥ 
Streptococcus mitis ATCC 49456 - 
Staphylococcus aureus Clinical Isolate - 
Enterococcus faecalis ATCC 29212 - 
Vancomycin resistant Enterococcus faecalis ATCC 51299 - 
 
*=includes all but one member of the South African strain collection, ATCC 
700669, and the four lanM positive strains from the University of Michigan clinical 
isolate collection.  
+= zone of clearance was detected. 
-= no inhibitory activity was detected. 
¥= the number of strains killed over the total number of strains tested 
 
2.2.9 Pneumolancidin producing strains have an advantage in invasion of 
colonization in vivo. 
To determine if pneumolancidin production provides a competitive advantage 
during colonization we compared the ability of a producing strain to invade a 
colonized mucosal surface to an otherwise isogenic non-producer.  Using a 
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staggered inoculation model, colonization was first established with the sensitive 
P174∆pldK strain for three days followed by introduction of either producer 
P174stR or non-producer P174 ∆pldA1-4. P174stR was able to invade the 
established community of P174∆pldK in the nasopharynx better than P174 
∆pldA1-4 (Fig. 2.5). Levels of P174∆pldK were lower in the mice inoculated with 
the wildtype strain suggesting that colonization results in the eviction of some 
resident organisms, however this difference was not statistically significant.  To 
account for difference in overall colonization density, we assessed the ratio of 
invading to resident (I/R) CFU per mouse in each condition.  While, only 1 of 20 
of the P174 ∆pldA1-4 inoculated mice had an I/R greater than 1, 7/19 mice 
inoculated with the wildtype strain had a predominance of the invading strain 
(Fig. A3). 
 
Figure 2.5. Competitive advantage of the pld locus in vivo. Mice were either 
colonized with P174ΔpldK or sterile PBS at day zero. At day 3, mice were 
challenged intranasally with either P174 or P174ΔpldA1-4. Nasal washes were 
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obtained 3 days post inoculation and CFU calculated by differential plating. Data 
for P174 are shown in purple, P174ΔpldK in red and P174ΔpldA1-4 in blue. 
Median and interquartile range are shown. Dotted line indicates the limit of 
detection (L.O.D). Statistical analysis was perfomed using an unpaired Mann-
Whitney test. * = p<0.05. **=p<0.01.  
 
2.2.10 Identification and characterization of additional strains with a pld-like 
locus. 
P130, which has immunity to pneumolancidin was shown to encode a pld 
locus by PCR and sequencing. The locus in P130 has the same gene content as 
P174, but overlay assays failed to demonstrate any evidence of lantibiotic-
mediated inhibition. The pld locus of P130 is nearly identical to the locus in the 
previously identified PN1 strain and the fully sequenced BHN418 strain and does 
not contain any large deletions or frameshift mutations that might account for the 
lack of activity. MLST analysis of the pld positive strains P174, P130, BHN418, 
and PN1 was determined to assess their genetic similarity (Table A2). P130 and 
BHN418 differed by only a single MLST allele while P174 did not share any 
common alleles with these strains. It appears that acquisition of the pld locus is a 
relatively unique property of P174 because the locus is not found in three publicly 
available, fully sequenced strains (GA05245, GA17227 and GA41301) that share 
the same founder ST as P174 (ST242). In fact, these strains lack the associated 
ICE element all together suggesting that P174 may have recently acquired the 
element. 
To determine if more pneumococcal strains could be identified that contain 
the locus, we screened a collection of over 400 clinical isolates for the presence 
of the pldM gene using PCR. Four strains were identified and were categorized 
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by serotyping and MLST analysis (Table A2). One of the newly identified clinical 
isolates was found to be from the same clonal complex as BHN418 and P130, 
but this isolate was neither active nor immune to P174. Three NT isolates with 
the locus were identified as belonging to the 448 sequence type. A genome 
sequenced isolate from this same ST, MNZ14 was found to have a pld locus that 
encodes all of the elements found in P174 with the exception of an apparent 
disruption of the gene encoding the peptide transporter, pldT [116]. The three 
pldM positive NT isolates from our collection lacked both inhibition and immunity 
to P174 mediated inhibition (not shown). 
2.2.11 P130 contains an inactive locus due to a mutation in PldM. 
Using allelic replacement, lysates from P130 were used to transform P174 
containing an exchangeable cassette replacing the entire pld locus. All of the 
resulting transformants lacked inhibitory activity suggesting that a mutation in the 
pld locus was responsible for the lack of P130 derived inhibitory activity. Amino 
acid sequence alignment of the PldM gene products from both strains 
demonstrated that the P130 strain contained a C867Y mutation in one of the 
critical residues required for zinc coordination (Fig.A4). It was shown previously 
that mutating any one of the conserved cysteine residues resulted in a loss of 
cyclization activity in the NisC enzyme [117]. To confirm that the mutation alone 
would result in a strain with P130 phenotype, the region of the pldM gene in P174 
containing the site of the mutation was exchanged with the P130 allele. The 
resulting strain, P174 PldM C869Y, was unable to inhibit (Fig.A4). Replacement 
of the P174 locus with the P130 pld versions of pldA1-4, pldF, and pldKR 
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resulted in a fully inhibitory strain (not shown) suggesting that the pldM mutation 
alone was responsible for the P130 phenotype. Reciprocal gain of function 
experiments in P130 could not be performed because P130 was not 
transformable.  
2.3  Discussion 
This work describes the first functional lantibiotic locus found in 
pneumococcus. The locus encodes the genes required for inhibitory activity 
against other pneumococci and closely related Gram positive organisms. It is 
found as cargo of an ICE element and has been identified in unrelated isolates 
suggesting that the locus is moving through the pneumococcal population via 
either conjugation or horizontal gene transfer. Not only has this locus 
disseminated in distinct pneumococcal lineages, but the two component system 
and pldFE genes of the locus share significant homology to a region in the S. 
mitis B6 genome. Genetic exchange between S. pneumoniae and S. mitis is 
common and contributes to the genomic diversity of the species [118]. The 
region of homology in the S. mitis B6 genome is sufficient for immunity to the pld 
peptides via the PldKR mediated upregulation of the PldFE ABC transporter. S. 
mitis ATCC 49456, was found to contain the pldK gene by PCR (data not 
shown). This isolate was immune to inhibition by P174 which may be due to the 
presence of the four pld genes, although without deletion analysis, the 
requirement for the pld homologues for immunity cannot be verified.   
All pneumococcal strains that we have identified apart from P174 that 
contain the pld locus lack inhibitory activity.  P130 has pld mediated immunity 
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that seems to derive from the pld locus. The mutation responsible for lack of 
inhibition was localized to a SNP within the pldM gene that results in the mutation 
of a critical residue involved in zinc coordination which is required for enzymatic 
activity of the modification enzyme. This same mutation is found in the 
sequenced strains PN1 and BHN418, perhaps explaining why no inhibitory 
activity has been attributed to these strains [99]. Disruption of the modification 
enzyme has been seen in the lantibiotic locus encoded by S. suis as way to 
prevent production of active lantibiotics but retain lantibiotic immunity [119]. Four 
other pneumococcal isolates were identified that were pld positive but these 
strains were not immune to P174, unlike P130. Loss of lantibiotic production may 
occur because of the energetic cost of production leading to the selection of a 
mutation rendering the locus nonfunctional. The energetic cost of the pld locus 
may be particularly high in pneumococcal strains due to in-vitro evidence of 
imperfect self-immunity demonstrated by plaque-like structure formation when 
strains are grown at high density.  Staggered colonization experiments 
demonstrate that pneumolancidin production does provide a competitive 
advantage in vivo, even in the relatively difficult task of invading an existing 
community.  Only 9 of 20 pre-colonized mice that were challenged with the non-
producing strain had evidence of any appreciable invasion, while 15 of 19 mice 
challenged with the producing strain were colonized with the invading strain.   
P174 lantibiotic peptides do not share homology to any other known lantibiotic 
peptides. Interestingly, the peptides are homologous to each other which may 
indicate a remote gene duplication event.  The tandem array of similar genes 
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encoding peptide antibiotics is reminiscent of some loci that encode the highly 
modified thiocillins.  Several of these loci are characterized by a tandem array of 
identical structural peptides that are modified by a series of enzymes to create 
the antibacterial molecule. The whole cluster of four structural peptides has been 
shown to be required for the antimicrobial activity of the tcl locus in Bacillus 
subtilis, however, to our knowledge, the requirement for multiple copies has not 
been explored but may be related to optimal gene dosage because a strain 
carrying a deletion of the four structural genes can be complemented with a 
single copy expressed on a multi-copy plasmid [120]. 
Other, more typical lan systems that express two structural peptides 
usually encode two separate modification enzymes where each is uniquely 
dedicated to the modification of one peptide [28, 57]. A seven lantibiotic peptide, 
cerecidin, in Bacillus cereus has been described that is associated with a single 
modification enzyme, although it was not shown to be functional in vivo [121]. We 
are currently working on purifying the active peptides to determine the specific 
role of each peptide in inhibition and stability. 
P174 is immune to its own lantibiotic although in overlay assays there is 
some degree of self-inhibition that is characterized by a halo of decreased growth 
around the stab. This phenotype is only seen when strains that can produce 
inhibition themselves are grown in the overlay. This may be indicative of a lapse 
in developing immunity in response to exogenous peptides when broth grown 
organisms are applied over stabs in which the locus has already been 
upregulated. When the overlay strain is placed over an actively secreting stab, 
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lantibiotic-mediated signaling derived from the stabbed strain activates some 
cells in the overlay and kills others. The activated overlay strains in turn kill or 
activate surrounding strains resulting in a wave of combined signaling and 
inhibition. The fact that the wave of signaling and inhibition requires signal 
propagation within the overlay strain is supported by the activity of the three 
reporter strains (pldA1-4 knockout, P174, and P174 act) with increasing ability to 
amplify the response to secreted signals and correlated increased zones of 
signaling when placed in overlay over P174.  
Although our inability to examine pld specific transcripts directly has 
hampered characterization of transcriptional control of the locus, we have 
described the activity of a series of reporter constructs in plate assays in an 
attempt to determine the likely transcriptional units. Unlike many other lantibiotic 
loci in which the entire cluster of lan genes is encoded on a single transcript, we 
have shown that the genes clusters downstream of pldA1-4 are controlled by 
separate promoters. The separate control of each of the gene clusters is further 
supported by the fact that plasmid integrations into the presumed promoters of 
pldFE, pldKR and pldM did not disrupt inhibitory activity. In fact, unlike the pldFE 
and pldM genes, the intervening pldKR genes are not upregulated in response to 
P174 peptide at all. The lack of peptide responsiveness of these genes may 
serve to dampen the positive feedback loop that occurs during peptide 
stimulation, by limiting the amount of regulatory proteins on the cell surface.    
We describe the identification of a serendipitously isolated hyperinducible strain. 
Based on the location of mutation in the presumed TATA box of the promoter 
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preceding pldFE and our results with the pldFE reporter strains, the most likely 
explanation of the phenotype is that the mutation affects expression of only 
pldFE, the proposed immunity transporter. Based on preliminary data, the variant 
phenotype of P174act seems to be attributable to decreased levels of PldFE, 
leading to increased sensitivity of the cell to exogenous peptides. The pldFEKR 
cluster falls in to the family of Bce regulatory/transporter proteins typified by the 
bacitracin resistance gene cluster BceRS-BceAB. In these cases, the transporter 
appears have dual role, functioning as a resistance protein by pumping out 
antibiotics and as a regulator interacting with the two component system to 
upregulate gene expression [122-124]. One possible interpretation of our findings 
is that altering the ratio of immunity transporter to regulatory gene products 
results in increased sensitivity to signaling peptide. Alternatively, it is possible 
that PldFE binds the Pld peptides with different affinity.  If this is true, then 
decreased production of the immunity transporter complex may change effective 
concentrations of the peptides. 
We have not yet tested whether the pld locus in P174 provides resistance 
against other cell wall targeting antimicrobials. Since bacitracin transporters often 
mediate resistance to other antibiotics, this could explain the maintenance of the 
pld locus in strains that are not producing functional lantibiotics [113-115].  
Wildtype P174 only produces appreciable pld mediated inhibition in plate grown 
organisms. This property has hampered our attempts at large-scale purification. 
We have noted, however, that the P174act strain can produce appreciable 
quantities of peptides during growth in broth, presumably due to the decreased 
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threshold for signaling. This mutant may serve as a useful tool for large-scale 
purification of this potent lantibiotic that inhibits nearly all pneumococcal strains 
tested. In addition the manipulation of immunity transporter quantities for 
increased yield of inhibitory peptides may be translatable for use in other lan 
systems with a bacitracin-like immunity transporter.   
We have shown that the P174 pld locus has the interesting property of 
requiring the presence of three very similar peptides for self-signaling to occur in 
a wildtype background. This may be a result of a gene dosage effect, such that 
three copies of nearly identical genes are required for to reach the threshold for 
activation; this assumes that all three peptides have the same function. 
Alternatively, the three peptides may form a complex and each peptide of the 
complex is uniquely required for signaling. The potential for separate roles of the 
individual peptides could not be assessed in the P174 background because the 
block in signaling does not allow us to assess differences in inhibition. In contrast 
to the individual peptide knockouts in the wildtype background, the individual 
knockouts in the P174act background each had a distinct phenotype, most likely 
due to the lower threshold for activation noted in this strain.  The phenotypes of 
individual peptide knockouts noted in this background confirm the absolute 
requirement for PldA3 for signaling. Of note, PldA3 is the most divergent of the 
three peptides, with two more cysteine amino acids in the active domain 
compared with PldA1 and 2 and would be predicted to have a very different 
structure. In addition, the single peptide deletions in the P174act background 
demonstrated that either PldA1 or PldA2 are sufficient to promote signal 
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secretion in combination with PldA3, but that PldA1 is more important for 
inhibition than PldA2. This may be either because more PldA1 is made than 
PldA2 or because the two peptides differ in their inhibitory activity on the target 
cell surface. We are currently working to isolate each of the three peptides to 
better understand their contribution to the remarkable anti-pneumococcal activity 
of pneumolancidin. 
 
2.4  Materials and Methods 
Bacterial strains, plasmids, and growth conditions 
All pneumococcal strains used are described in Table A2 and all primers used 
are described in Table A3. All pneumococcal strains were plated on either 5% 
sheep’s blood (SBA)  or tryptic soy agar plates (TSA)  with 0.5% catalase 
(Worthington, Lakewood, NJ) (4,741 U) and incubated at 37 °C with 5% CO2. 
For growth in liquid culture, all pneumococcal strains were grown in Todd-Hewitt 
broth supplemented with 0.5% yeast extract (THY). Escherichia coli strains were 
grown in Luria-Bertani (LB) broth or LB agar. 
All pneumococcal strains were plated on either 5% sheep’s blood (SBA)  
or tryptic soy agar plates (TSA)  with 0.5% catalase (Worthington, Lakewood, NJ) 
(4,741 U) and incubated at 37 °C with 5% CO2. For growth in liquid culture, all 
pneumococcal strains were grown in Todd-Hewitt broth supplemented with 0.5% 
yeast extract (THY). Escherichia coli strains were grown in Luria-Bertani (LB) 
broth or LB agar. Antibiotic concentrations used were as follows: for S. 
pneumoniae, 500 μg/ml kanamycin, 100 μg/ml streptomycin, 5 μg/ml of 
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neomycin, 2 μg/ml chloramphenicol, 1 μg/ml erythromycin, and 200 μg/ml 
spectinomycin; and for E. coli, 50 μg/ml kanamycin, 20 μg/ml chloramphenicol, 
100 μg/ml erythromycin, and 100 μg/ml spectinomycin. The South African 
collection of pneumococcal isolates has been previously described [93]. The 
clinical isolate collection consists of 457 disease causing pneumococcal isolates 
that were collected by the microbiology lab from existing patient samples at the 
University of Michigan between 2004 and 2006.    
Disruption of blp and com loci in P174 
To disrupt the blp or cib locus, P537 was made that contained the Janus 
cassette in place of the blp locus or P1535 that contained a Janus insertion at the 
comD gene [93, 125]. Genomic DNA was extracted from either P537 or P72 and 
used to transform competent P174. Colonies were selected for the presence of 
the Janus cassette by plating on kanamycin plates. Allelic exchange of the 
appropriate locus for the Janus was confirmed by PCR [125]. 
 
Transposon mutagenesis of P174 
 Mutagenesis of P174 genomic DNA was performed as previously 
described by van Opijnen et al., 2007[126]. The transposon mutagenized 
genomic DNA was then used to transform P174 and transposon insertion 
mutants selected on spectinomycin plates. Transformants were screened for loss 
of inhibitory activity by overlay assay using a 96 well replicator to stab the strains 
into agar plates. The overlay strain used was the universally sensitive 
pneumococcal strain, P537. Lysates of transformants unable to inhibit strain 
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P537 were used to back transform strain P174 and the original phenotype 
confirmed on overlay assay. Confirmed mutants were sequenced using universal 
transposon specific and universal primers as previously described to determine 
the location of the transposon insertion [126]. The entire pld locus from P174 and 
P130 was sequenced by using a combination of chromosome walking and 
plasmid rescue.   
 
Construction of individual pldA deletions, whole peptide deletions, and 
complementation.  
In frame, unmarked deletions of the genes encoding individual peptides 
were constructed using the counter-selectable  Janus cassette. First, the pldA1-4 
region plus 500bp up- and downstream was amplified using primers 1 and 2. 
This product was cloned into pCR2.1 generating plasmid pE93. A blunt-ended 
janus cassette amplified using primers 5 and 6 was ligated into an inverse PCR 
product generated using primers 3 and 4. A streptomycin resistant version of 
P174 was transformed with the ligation product creating P174 pldA1-4::Janus 
[127]. This strain, containing the Janus cassette in place of the four putative 
peptide ORFs was used to make individual peptide and whole peptide deletions. 
Four separate inverse PCR reactions followed by plasmid religation were 
performed on plasmid E93 to create individual in frame unmarked deletions of 
the individual peptides using primer pairs 7 and 8, 9 and 10, 11 and 12 and 13 
and 14. Primers 3 and 4 were used to create an unmarked whole deletion of the 
peptide region.  Resultant plasmids were transformed into P174 pldA1-4::Janus. 
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All transformants were verified by PCR using primers 7 and 14 and sequenced to 
ensure the absence of PCR generated mutations. To complement P174pldA1-
4::Janus, E93 was used to transform back all four of the peptides and the 
resulting strain tested for inhibition and immunity.  
 
Disruption or deletions of other genes in lan locus. 
To disrupt pldK and pldT, a small internal fragment of both genes was 
amplified using either primer pair 15 and 16, or 17 and 18, respectively. Both 
PCR products were cloned into pCR2.1 and then moved into E68, an integrative 
plasmid with the spectinomycin resistance gene.  The resulting plasmids were 
used for transformation into P174 and plated on spectinomycin plates. 
Transformants were PCR verified using forward primer 15 or 17 for either the 
pldK or the pldT, respectively, and either primer 19 or 20 to determine 
orientation. 
Disruption of pldM was achieved by using the transposon mutant identified 
in the transposon mutagenesis screen. To verify inhibitory activity was 
attributable to disruption of lanM, lysates were prepared from the original 
transposon mutant andre-transformed into P174. To delete pldEF, an in-frame, 
unmarked deletion of this region was made by allelic exchange. The Janus 
cassette was amplified from P174pldA1-4::Janus using primer pair 1 and 23 
creating a NsiI site at the 3’ end of the Janus. This PCR product was digested 
with NsiI and ligated to the NsiI digested PCR product of 22 and 16. The ligated 
product was transformed into P174strepR kanamycin resistant transformants 
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were verified by size by PCR with primers 1 and 16. To generate a pldFE 
deletion, PCR products using  primer pair 1 and 21 and primer pair 22 and 16 
were ligated and transformed into P174pldA1-4EF::Janus with selection on 
streptomycin.  The appropriate deletion was confirmed by PCR and sequencing. 
To create a 4 bp deletion in the intergenic region between pldA4 and 
pldFE which included the site of the mutation, the Janus cassette was extended 
from P174pldA1-4::Janus to cover the site of the mutation. The Janus from 
P174pldA1-4::Janus was amplified using primer pair 1 and 23 and ligated to the 
product of primer pair 33 and 34 after digestion with NsiI. The ligated product 
was transformed into P174strepR, resulting in P174pldA1-4mut::Janus. Next, site 
directed mutagenesis was used on plasmid E93 using primer pair 35 and 36 the 
resulting product used to transform P174pldA1-4mut::Janus. The mutation was 
verified by sequencing. 
 
Construction of Reporter Plasmid and Strains 
The reporter plasmid was constructed in a derivative of the lacZ containing 
integrative plasmid, pEVP3.  This plasmid was first made kanamycin-resistant 
due to the inherent chloramphenicol resistance of P174. The kanamycin 
resistance cassette was added to pEVP3 at a unique EcoRI site creating plasmid 
E65. A PCR product containing 500bp upstream of the pldM gene and the first 
207 nt of the pldM coding sequence was amplified using primer pair 24 and 25. 
This product was cloned into E63 creating a transcriptional fusion of the pldM 
promoter and lacZ. This reporter plasmid was used to transform P174, P174 
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∆pldA3, or in P174act and transformants selected on kanamycin. Colonies were 
screened using primer pair 24 and 26.  
To generate the pldK reporter, a 500bp fragment containing 451 bp 
upstream of pldK through the first 15 codons was amplified with primer pair 37 
and 38. This PCR product was cloned into pE65 into unique XbaI and NsiI sites. 
The resulting plasmid E180 was transformed into either P174 or P174act.  To 
generate the pldF-lacZ fusion strain, a 500 bp fragment containing the first 36 bp 
of pldF from either P174 or P174act was cloned into E65 using XbaI and NsiI 
sites with primer pair 39 and 40. The resulting plasmid E181 or E182, containing 
P174 or P174act DNA, respectively, was then transformed into either P174 or 
P174act. Confirmation of correct integration of the plasmid was done using 
primer pair 39 and 26. To generate a pldA1-lacZ fusion, a PCR product 
containing approximately 500 bp upstream of pldA1 and through the first 13 
codons of pldA1 was generated and cloned into E65 using XbaI and NsiI sites 
with primer pair 47 and 48. The resulting plasmid E188 was transformed into 
either P174 or P174act. Transformants were verified with primer pair 47 and 26.  
 
Linkage analysis  
To demonstrate that the lack of inhibitory activity in P130 was linked to the 
pld locus, an exchangeable Janus cassette was used to replace the entire pld 
locus of P174. The deletion was created by ligating the product of primer pair 1 
and 23 on P174 pldA1-4::Janus to the product of primer pair 39 and 40 from 
P174 and transforming into P174 strepR. The correct insertion was verified using 
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primer pairs 1 and 40. P174 pldA1-4EFKRMT::Janus was transformed with 
genomic DNA of P130 and selected on streptomycin.  Transformants were 
verified by PCR. 
To make the specific mutation in pldM in the P174 background, a Janus 
cassette was introduced into a unique BsrGI site in a cloned version of pldM 
made using primer pair 41 and 42. The resulting ligation was then transformed 
into P174 strepR, creating P174 pldM::Janus. Verification of transformants was 
done using primer pair 41 and 42. To exchange just the area of difference 
between the two alleles, P174 pldM::Janus was transformed with a PCR product 
from P130 produced using primer pair 45 and 46. 
 
Overlay assays for inhibition, signaling, and immunity 
Overlay assays were used to screen inhibition , immunity and signaling  
were performed as described previously [128].  All overlays were repeated at 
least three times and performed on three separate occasions to evaluate for 
consistency to the methods.  To test activity of supernatants on plates obtained 
from P174act grown to an OD620 of 0.5, a lawn of a reporter strain was spread 
onto a TS plate containing X-gal and catalase. Spots of the filter sterilized 
supernatants were added on top of the dried lawn and then incubated at 37°C 
overnight. 
 
Screening of the South African and Clinical Isolate Collection for lan genes 
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To identify other strains that might possess the pld locus, the collection 
was screened by PCR using primers 27 and 28 that amplified an internal 
conserved region of pldM. Reactions were run on an agarose gel and the 
presence of a 300 bp band indicated pldM positive strain. To determine if these 
strains had the same peptide region as P174 any positive strains were also 
screened with primers 31 and 32. 
 
MLST of clinical isolates 
MLST analysis was performed by sequencing the seven housekeeping 
genes using previously described methods [129].  Sequences obtained from 
using universal primers for each allele were entered into the website 




Reporter strains containing pldF-lacZ  in either P174 or P174 act background 
were grown to an OD of 0.2, 40µl was added to a microtiter plate containing 
catalase and either 40 µl of supernatants from ∆pldK or from P174 act that was 
diluted in two fold serial dilutions in THY. Plates were incubated for 1.5 hours and 
Miller Units determined as described [130, 131]. 
Staggered mouse colonization assays 
All mice were purchased from Jackson laboratories and were housed in 
accordance with Institutional Animal Care and Use Committee protocols. This 
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protocol was described previously with some modifications [90]. Ten 6 to 7-week-
old BALB/c mice were inoculated intranasally with 10 μl containing 4 × 107 CFU 
of animal passaged strain of P174 ∆pldK resuspended in PBS. At 3 days post 
inoculation,  approximately 107 CFU of either animal passaged P174 strepR or 
P174 ∆pldA1-4 strepR  were intranasally inoculated into  mice either previously 
colonized with P174 ∆pldK or PBS. Five control mice received PBS followed by 
the two invading strains.  After three days, mice were sacrificed and nasal 
washes were collected by tracheal lavage using 200µl of PBS. The lavage fluid 
was diluted in PBS and plated on TSA with selection.  All plates contained 
neomycin to prevent growth of the natural flora. Strains were differentiated on 
streptomycin or spectinomycin containing media.  The experiment was repeated 
once and the cumulative data from both experiments is shown. One mouse in the 
producer arm died during the course of the experiment, colonization for this 
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CHAPTER III 
 
LANTIBIOTIC PEPTIDES, PNEUMOLANCIDIN A1 AND A3, OF 
STREPTOCOCCUS PNEUMONIAE HAVE DIFFERENT BIOACTIVITIES 
DESPITE STRUCTURAL SIMILARITIES 
 
Abstract 
Lantibiotics undergo posttranslational modifications that result in the 
creation of lanthionine or methyllanthione rings that are required for their function 
both as antimicrobials and autoinducers. Two-peptide lantibiotics require the 
actions of two modification enzymes and are structurally different. This difference 
in structures contributes to their specialized role in inhibition. Recently, a 
lantibiotic locus, encoding pneumolancidin (pld), was found in Streptococcus 
pneumoniae.  This locus contains four open reading frames arranged in a 
tandem array that are predicted to encode four highly homologous lantibiotic 
peptides. A gene encoding a single modification enzyme, pldM, was found in the 
locus suggesting that the four Pld peptides might be modified by the same 
enzyme and thus adopt similar structures. Our previous data demonstrate that 
these peptides, despite significant homology, have specialized functions related 
to the antimicrobial and autoinduction function of the lantibiotic locus. Using 
genetic analysis, it was shown that the Pld peptides (1-3) play specialized and 
unique roles in inhibition and the ability to upregulate the locus. In the WT setting, 
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each peptide was required for inhibition. This could be explained by a 
requirement for a specific gene dosage rather than a requirement for the 
individual properties of each peptide.  To determine if gene dosage rather than 
unique activity attributable to each peptide might explain the requirement for all 
three Pld peptides, we created a pld locus that contained a pldA1 duplication that 
replaced the ORF of pldA2. If gene dosage alone explained the requirement for 
pldA2, then we predicted that this strain would retain inhibitory activity.  However, 
this strain was not able to kill or signal arguing in favor or a specific role for 
PldA2. Additionally, expression of PldA3 alone was not sufficient to kill or signal 
in the WT (P174) or lab generated hyperinducible strain (P174act) background 
despite being required for signaling.  This data combined suggests that a 
complex may be required for activity consisting of PldA3 and at least one other 
Pld peptide. The structures of pneumolancidin A1 and A3 from Streptococcus 
pneumoniae have been solved using nuclear magnetic resonance spectroscopy 
(NMR) and tandem mass spectrometry (MS/MS). Purified PldA1 and PldA3 were 
found to be structurally homologous but with distinct functions that were not 
consistent with genetic analysis. Despite having similar structures, PldA1 was 
only able to upregulate the pld locus in a reporter strain but did not have any 
inhibitory activity while PldA3 was able to inhibit a sensitive strain but lacked 
evidence of signaling activity. The Pld peptide structures will provide further 
insight into structure-function relationships. 
. 
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3.1 Introduction 
Lantibiotics are a class of bacteriocins that undergo posttranslational 
modifications resulting in creation of lanthionine or methyllanthione residues [6]. 
Creation of these residues involves the dehydration of serines and threonines 
which are then linked to cysteines via a thioether bridge. In type II lantibiotics, the 
dehydration and thioether formation is catalyzed by a single enzyme, LanM [24]. 
In type I lantibiotics, two modification enzymes are required for both dehydration 
and cyclization, LanB and LanC, respectively [11-14]. After modification, the 
prelantibiotic peptide is secreted by a dedicated ABC transporter encoded by 
LanT [14]. The signal peptide which is needed both for recognition by the 
modification enzyme is then either cleaved by LanT or by an outer membrane 
protease, LanP [16, 25, 26]. After cleavage of the signal peptide, the lantibiotic is 
functional. Lantibiotics exert an antimicrobial effect by targeting lipid II, an 
important cell wall precursor, and some lantibiotics are capable of subsequent 
pore formation [45-47, 56]. Lantibiotics act as signaling pheromones and are able 
to interact with a cognate histidine kinase, LanK, initiating transcription of the lan 
locus [18, 111, 112]. Immunity is conferred by either an ABC transporter and/or 
an immunity protein, LanI [63, 71, 72, 132].  
Streptococcus pneumoniae is known to secrete antimicrobial peptides 
called bacteriocins, an important mediator of competition [90, 93, 96, 106]. 
Although putative lantibiotic loci are encoded in many pneumococcal strains it is 
unknown if expression of these lantibiotics occur [97-101].  We recently 
described the first functional lantibiotic locus in a clinical isolate of 
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pneumococcus, P174 [133]. The pneumolanicidin (pld) locus of P174 encodes 
four highly homolous Pld peptides. This locus only encodes a single modification 
enzyme, PldM, unlike other examples of multi-peptide lantibiotic loci, suggesting 
that the structures of the peptides may be similar. Using genetic analysis, we 
found three of the four peptides, PldA1-3, were required for both inhibition and 
signaling of the reporter strain. A hyperinducible mutant strain (P174act) was 
discovered in which a lowered threshold of exogenous Pld peptides was needed 
for activation. When individual PldA deletions were tested in this background , 
the Pld peptides were found to have specialized roles.  A PldA1 deletion in 
P174act was found to secrete a signal but inhibition was lost, a PldA2 deletion 
strain was able to signal and inhibit, and a PldA3 deletion strain did not inhibit or 
signal. This suggested that PldA1 was important for inhibition, PldA2 was 
dispensable for inhibition and signaling, and PldA3 was required for signaling 
with an undetermined role in inhibition. To better dissect the role of these Pld 
peptides, we tested the bioactivity of purified Pld peptides against 
pneumococcus. 
The pld locus has been found in a number of pneumococcal strains and in 
Streptococcus salivarus, however the structure of the Pld peptides has not been 
solved [99, 134]. From a structure perspective, lantibiotics can be separated in to 
two classes that predict their activity. Type-A lantibiotics have a linear structure 
that is important for forming pores in the membranes of sensitive strains [47]. 
Type-B lantibiotics are globular in shape and do not form pores but bind to lipid II 
[53]. In the case of known two-peptide lantibiotics, one is typically structurally 
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similar to type-A and the other is similar to type-B [135]. The Pld peptides do not 
share homology with any known lantibiotics so structure predictions could not be 
made based on primary sequence alone. To better understand the function of 
these unique peptides, we purified two of the three functional peptides and 
determined their structure using a combination of MS/MS and NMR.  Here we 
demonstrate that despite the similarity in structures of the Pld peptides, they are 
able to play specialized roles in antimicrobial activity and auto-induction which 
may require complex formation. 
 
3.2 Results 
3.2.1 Gene dosage is not a contributing factor for functioning of Pld peptides and 
PldA3 alone does not activate the pld locus 
We previously showed that individual in-frame unmarked deletions of the 
genes encoding the first three petides, PldA1, 2 or 3 resulted in a strain that 
could neither inhibit nor upregulate the locus in the reporter strain. A deletion of 
the gene encoding the last putative peptide, PldA4, did not result in loss of 
signaling or inhibition. This suggested that in the WT setting, PldA1-3 were 
required for signaling to occur, most likely forming a complex that is recognized 
by PldK. Since the peptides are homologous to one another, a deletion of the 
genes encoding any of the three functional peptides, PldA1-3, could perturb the 
stoichiometry that is needed for optimal activity. To test this hypothesis, a 
duplication of pldA1 was made in place of pldA2, essentially creating a pldA2 
deletion with a pldA1 duplication. Although PldA2 was deleted, the relative ratio 
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of Pld peptides to PldFE should be unchanged as compared to the WT 
containing PldA1-4. The resulting strain, P174pldA1+/∆pldA2::pldA1 was unable 
to inhibit or signal suggesting that altered gene dosage does not explain the 
phenotype of how the Pld peptides might be functioning (Fig 3.1). 
Peptide deletions created in the hyperinducible strain, P174act, had 
distinct phenotypes.  P174act∆pldA1 could not inhibit but could still secrete a 
signal indicating that PldA1 may be important for inhibition but was dispensable 
for signaling, at least in this background. P174act∆pldA2 was able to inhibit and 
signal suggesting that the role of PldA2 was dispensable in this background. 
P174act∆pldA3 was unable to inhibit or signal suggesting that PldA3 is required 
for signaling at a minimum, its role in inhibition could not be assessed using a 
genetic approach. We had shown previously that the mutant, P174act, required 
less of the Pld peptides for activation of the locus. Since the mutation in P174act 
results in the  downregulation of the genes encoding the immunity transporter, 
PldFE, it is possible that excess of PldFE might play a role in sequestering free 
peptides.  
Since PldA3 was required in both wildtype and P174 act backgrounds for 
both signaling and inhibition, strains were constructed that only expressed PldA3 
and PldA4 in either P174 or P174act backgrounds. Consistent with previous 
data, the pldA1-2 deletion containing strain, P174∆pldA1∆pldA2 ,did not exhibit 
any inhibitory or signaling activity.  Because we had previously shown that in 
P174act, expression of PldA3 in combination with either PldA1 or PldA2 was 
sufficient for signaling,we wanted to determine if PldA3 alone was sufficient for 
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signaling when expressed in this background. P174act∆pldA1∆pldA2 was unable 
to inhibit or signal the reporter strain suggesting that at least one other Pld 
peptide, either PldA1 or PldA2, is needed for signaling to occur (Fig. 3.1). 
 
Figure 3.1. Evaluation of signaling and inhibition in either PldA1 duplication 
or PldA3 only expressing strains. Inhibition and signal secretion was assessed 
using the overlay assay. For the overlays, each strain was stabbed onto an agar 
plate and then overlaid with either a Pld sensitive strain, TGR4, or a reporter 
strain P174pldM-lacZ to detect either inhibition or signal secretion, respectively. 
As controls, P174 and P174act were included for comparison. 
 
3.2.2 Purified PldA1 and PldA3 have different bioactivities and undergo a 
secondary cleavage event 
To gain a better understanding of the role of the Pld peptides, we separated the 
Pld peptides by purification to test their bioactivity directly. Since expression of 
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Pld peptides is only seen with growth on solid media, multiple stabs of P174act 
were made onto BSA plates. Broth media, THY, was overlaid on top of the 
plates. The 5.5L of media, containing Pld peptides, was collected and subjected 
to an organic resin extraction. Three different solvents, methanol, ethanol, and 
propanol were used to elute the Pld peptides from the resin. Of the three, the 
ethanol with 0.1%TFA contained the most Pld peptides based on activity of 
fractions upon dilution (Fig. 3.2). The specific activity of the ethanol fraction was 
higher as compared to either methanol or propanol fractions (Fig.3.2).  
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Figure 3.2. Inhibitory and signaling activity of different solvents used for 
elution of Pld peptides from resin. The following solvents, 80% methanol, 
ethanol with 0.1%TFA, and propanol with 0.1% TFA were used sequentially to 
wash the resin beads. To quantify the amount of Pld peptides that were eluted, 
serial dilutions starting from 20mg/ml of total protein were made and 5 µl were 
spotted on either a plate containing a lawn of a Pld sensitive strain, TGR4, to 
assess inhibition (A) or a plate containing a lawn of reporter strain, P174pldM-
lacZ, to detect exogenous Pld peptides (B). Ethanol with 0.1% TFA exhibited 
inhibition and signaling at higher dilutions as compared to either 80% methanol 
or propanol. Signaling activity of propanol eluted resin fraction was not seen and 
not included in the above figure (B). DMSO was also included as a control and 
did not exhibit inhibition or signaling activity (not shown). 
 
The ethanol fraction collected from P174act was subjected to HPLC analysis. To 
determine which peaks may contain Pld peptides.  P174∆pldK was used as a 
control to determine relevant peaks to collect for purification since Pld peptide 
production is abrogated in this mutant. Peaks absent in the chromatogram of 
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P174∆pldK but present in  P174act represented potential peaks containing Pld 
peptides. Using this comparison, peaks 1-6 were collected and tested for 
inhibition and signaling. Two peaks, 3 and 6, were identified that contained PldA1 
and PldA3 based on MS/MS analysis (Fig 3.3,B1,B9).  The fraction containing 
PldA1 was able to activate the reporter strain but could not inhibit the sensitive 
strain. The fraction containing PldA3 was able to inhibit a sensitive strain, albeit 
at a higher concentration than expected, but this substance could not upregulate 
the reporter strain. The specialized roles determined for each purified Pld peptide 
was in direct contrast to what was previously deduced using information from the 
individual peptide deletions [136].  
 
Figure 3.3 HPLC purification of Pld peptides and bioactivity. Reverse-phase 
HPLC separation of the peptides was done using a C-8 column. Each numbered 
peak represents a fraction that was collected and assayed for inhibition or 
signaling by pipetting 5µl spots of a 0.1mg/µl starting concentration dissolved in 
DMSO to either a lawn of a Pld sensitive strain, TGR4, or a reporter strain, 
P174pldM-lacZ, respectively. Peaks in which PldA3 and PldA1 were found are 
shown by arrows along with an inset depicting their bioactivity. Additionally, a 
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fragment containing the first eight N-terminal amino acids was found in peak 1 
but did not contain activity. 
 
Purified PldA1 was unstable as attempts to quantify the activity of PldA1 failed 
and activity could not be reproduced. Additionally, upon dilution of PldA3 to 
determine the MIC, inhibition was seen only at a two-fold dilution and activity was 
lost at higher dilutions. The instability and low activity prevented any synergistic 
activity experiments.  
3.2.3 PldA1 and PldA3 are structurally similar and found to undergo a secondary 
processing event 
Structures of PldA1 and PldA3 were elucidated using extensive 1D/2D 
NMR and HRMS/MS studies (Appendix B). The predicted amino acid sequence 
of PldA3 acted as preliminary template towards the primary structure of the 
peptide but the monoisotopic mass of [M- 3H2O+H]+ was observed to be 
2511.3772 Da, suggesting further modifications. We proceeded with MS/MS 
mass spectrometry data for initial characterization, which suggested that PldA3 
was truncated eight amino acids (between lysine and methionine) after the 
predicted leader sequence cleavage site. The truncated N-terminus of PldA3 was 
detected by MS/MS in peak 1 during HPLC purification, suggesting that a 
secondary processing event is occurring outside of the cell (Figs.B3 and 3.3). .  
To determine structures, NMR spectroscopic data were obtained for PldA3 
(Fig.B4-8). In addition, HSQC spectra unambiguously established no aliphatic 
unsaturation by absence of NMR signal in pre-requisite spectral region of 5.0 – 
6.5 ppm, confirming the absence of Dha and Dhb residues in PldA3( Fig. B6).  
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The Lan/MeLan rings in PldA3 were established with short range NOESY, 
(Fig.B7). The C-terminal MeLan spin system S--Ala24-His23-Val22-Asn21-
Asn20-Abu19—S was established based on NOE observed between assigned 
downfield Ala24-Hα (4.17 ppm) and Thr18-β (3.38 ppm) along with correlation 
between NH doublet at 7.25 ppm, CH singlet at 6.71 ppm in His23 ring residues 
and Thr18-Hβ proton at 3.79 ppm. Moreover, the largest MeLan ring in PldA3 
between S-Ala17 and Abu2 was assigned through an unequivocal NOE 
observed between Thr18-β (3.38 ppm) and CH3 singlet at 1.73 ppm in Met1; the 
spin system also showed distinct connectivity between Ala17-Hα (4.18 ppm), 
NH17 (7.74 ppm) and CH3 doublets in Leu3 (1.10 and 0.99 ppm).  
A similar experimental approach using HR MS/MS and extensive 1D/ 2D 
NMR was followed to determine the structure of PldA1(Fig. B9-13). Pld A1 
showed a high resolution time of flight electrospray ionization mass spectrometry 
(ESIMS) [M-2H2O+H]+ ion peak at m/z 2610.4430. Again, the observed m/z for 
PldA1 was less than calculated m/z of mature peptide, indicating truncation in 
PldA1 apart from predicted leader peptide cleavage side, which corresponded to 
removal of the first 7 amino acids at the N-terminus. As in the case of PldA3, 
fragmentation between amino acids situated within the Lan and MeLan rings is 
typically not observed by MS/MS, enabling us to map out topological ring 
systems in PldA1. Interestingly, unlike PldA3, here all the Cys residues were 
observed to be involved in forming Lan/ MeLan rings. All Lan/MeLan rings were 
confirmed with NOESY (Fig.B13).  
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To affirm the MS/MS fragmentation and structural obscurities, 2D 
gHSQCAD, gCOSY and NOESY spectrums were recorded in CD3OD -d6 (Fig. 
B11-13). Interestingly, PldA1 contained an isopeptide linkage between Glu16 and 
Lys23 which was confirmed by NOESY and MS/MS (Fig. B9 & B13). Although 
the presence of an isopeptide in a lantibiotic peptide has not been described 
before, it may be important in maintaining the correct shape and protein stability 
which is needed for PldA1’s role in signaling. The isopeptide bond has been 
shown to be important for providing thermal stability and protection against 
proteolysis in other proteins such as pili [137]. Furthermore, there were no 
chemical shifts observed within the expected spectral region of 5.0-6.5 ppm in 
gHSQCAD, ruling out the possibility of any dehydration of Thr14 and Thr18 for 
completing the structure of PldA1 (Fig. B11). 
 
Figure 3.4 Deduced structures of PldA1 and PldA3. The structures of both 
PldA1 and PldA3 are shown above and resemble type-B lantibiotics.  Both 
peptides contain a single lanthionine (Ala-S-Ala) and either two methyllanthionine 
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rings (Abu-S-Ala) in PldA1 or three methyllanthionines in PldA3. PldA3 contains 




 This work describes the structural characterization of two pneumolancidin 
peptides, PldA1 and PldA3, which are secreted by a clinical isolate of 
pneumococcus, P174. We had previously shown using genetic analysis that 
PldA3 is required for upregulation of the pld locus because strains with a PldA3 
deletion in either the wildtype P174 or P174act background lacked evidence of 
signaling or inhibition.  Genetic analysis also suggested that PldA1 was required 
for inhibition as a pldA1 knockout in the P174act background lacked evidence of 
inhibition, but retained the ability to upregulate the locus of the reporter strain 
[133]. We hypothesized that gene dosage might be playing a role in how these 
peptides function because PldA1 and PldA2 are nearly identical in sequence. 
The intergenic region upstream of pldA2 was retained in the construction of the 
PldA1 duplication to eliminate any possibility that the intergenic region might be 
important in the difference of function.  There are examples of lantibiotics in 
which the ratios of peptides is controlled by gene dosage, and is important for 
their biological activity. For example, Bacillus cereus SJI encodes three precursor 
lantibiotic peptides named bicereucin [138]. Two of the peptides, BsjA1 and 
BsjA3, are identical in sequence, and were found to exhibit synergistic 
antimicrobial activity with BsjA2 in a 2:1 ratio [138]. Hence, two copies of BsjA1 
are needed to form the optimal ratio needed for antimicrobial effect.  Given this 
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example from a similar system, we thought gene dosage may explain the 
requirement for all three Pld peptides in the WT background.  PldA1 and PldA2 
differ by only two amino acids, F15Y and T19S, in the active peptide sequence 
with F15Y representing a conserved change in overall shape of the two amino 
acids. A deletion of the gene encoding either PldA1 or PldA2 in a P174 
background resulted in a strain that did not signaling activity. We reasoned that if 
gene dosage was the explanation for the requirement for both PldA1 and PldA2 
rather than any unique function for the peptides, increasing the amount of PldA1 
in a strain deficient in PldA2 would restore the strain to wildtype function. 
However, signaling was not restored in the ∆pldA2 strain expressing the PldA1 
duplication indicating that gene dosage is not the explanation for the requirement 
for both peptides.  We are currently creating a  pldA1 duplication in the P174act 
background.  We hypothesize that this strain should look identical to the pldA2 
deletion strain in this background with wildtype inhibition and signaling.   
 Compared with the single pldA1 or pldA2 mutations in the P174act 
background, a deletion of both pldA1 and pldA2 resulted in a complete loss of 
activity supporting the hypothesis that complex formation may needed for 
recognition by PldK  [133]. Specifically, PldA3 might require either PldA1 or 
PldA2 to form a signaling complex. When examining the function of the purified 
peptides, PldA3 alone inhibits a Pld sensitive strain but does not signal our 
reporter strain (Fig.3.3). Conversely, purified PldA1 upregulates the pld locus in 
the reporter strain but lacks evidence of inhibition (Fig. 3.3). Based on the 
instability of purified PldA1, this would suggest the role of PldA3 as a stabilizing 
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factor for PldA1 and possibly PldA2. Without PldA3, PldA1 is unstable and 
cannot signal the reporter strain nor inhibit which is the case when pldA3  is 
deleted in both P174 and P174act [133]. Since we were not able to recover 
purified PldA2, it was not possible to determine its role in either signaling or 
inhibition. PldA2 seems to play a less important role in inhibition as compared to 
PldA1 based on the loss of inhibition that is observed when PldA2 and PldA3 are 
expressed but not when PldA1 and PldA3 are expressed.  Although, the PldA1 
duplication replacing PldA2 was not sufficient to recover inhibitory activity it may 
indicate that relative ratios of each peptide may be important in forming a 
functional complex. Currently, we do not know the expression levels of these Pld 
peptides or the stoichiometric requirement of these complexes. Additionally, it is 
unknown if PldA3 can inhibit in complex with PldA1, or if the formation of this 
complex is just needed for signaling. Another possibility is that PldA3 may be 
required to stabilize either PldA1 or PldA2 or both. In the absence of PldA3 in 
either P174 or P174act, inhibition and signaling is abrogated which may be 
explained by the fact that without PldA3, PldA1 and/or PldA2 are unstable and 
therefore, nonfunctional (Fig. 3.1). This may also be the reason why purified 
PldA1 is unstable. In the future, we plan to study the stability of PldA1 with and 
without PldA3. 
 Since lantibiotics are known to exert an antimicrobial effect at even 
nanomolar concentrations, it was puzzling that PldA3 was not able to inhibit at 
more than two fold dilution.  One hypothesis might be that the secondary 
cleavage event was an artifact of the purification strategy and might not 
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represent the functional peptides in vivo. To address this issue, Laser Ablation 
Electrospray Ionization (LAESI) -MS will be used to analyze the lantibiotic 
peptides that are found in the zone of clearance of overlay plates.  A secondary 
cleavage event was not predicted because the pld locus does not encode a 
second protease that would be predicted to cleave beyond the typical GG motif 
recognized by PldT during export. Some lan loci do not encode either a LanT- or 
LanP-like protease. Instead, proteolytic cleavage is achieved by co-opting a 
protease not encoded by the lan locus. In the case of subtilin, three different 
serine proteases not encoded in the subtilin locus, were able to cleave the leader 
peptide [17]. Other lan loci encoding type II lantibiotics, such as cytolysin and 
bicereucin, encode a dedicated protease in addition to the ABC transporter 
containing a peptidase domain [60, 138]. To identify a protease, a PCR of P174 
was performed to detect the presence of a surface exposed serine protease 
named Subtilase Family Protein (SFP). SFP was identified in D39 and was found 
to play a minimal role in virulence [139]. However, PCR did not detect the 
presence of the gene ecoding SPF in P174 suggesting that there might be 
another protease present.  Genomic sequencing of P174 is currently being 
performed which may help to identify other proteases that might contribute to 
PldA processing.  
 The structures of PldA1 and PldA3 resemble the globular lantibiotics of the 
type-B classification similar to the well characterized lantibiotic, mersacidin. 
Mersacidin binds to lipid II but does not form pores in membranes. PldA3 might 
also be able to bind lipid II but further experiments are needed to confirm 
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mechanism of action. Interestingly, the Pld peptides play specialized roles 
despite sharing similar structures. Site directed mutagenesis will need to be done 
to identify residues that are required for signaling and those required for 
inhibition. PldA3 contains an extra methyllanthionine that may be important for 
inhibition. Interestingly, PldA1 contains an isopeptide bond that has been found 
in other proteins to play an important role in maintaining protein shape and 
rigidity [137]. It is possible that the isopeptide bond is needed for the correct 
structure to interact with PldK and would be a likely candidate for mutagenesis. It 
is also possible that the methyllanthionine ring in PldA1 which is replaced by a 
lanthionine ring in PldA2 might play an important role in antimicrobial activity. 
Despite similar structures, the Pld peptides are specialized and able to perform 
diverse functions, reminiscent of the Enterococcal lantibiotic, cytolysin. Cytolysin 
consists of two peptides, CylLL″ and CylLS″, that form an inactive complex when 
target cells are abscent.  When bacteria encounter target cells, CylLL″ has a 
higher affinity for membranes than CylLs.  CylLL binding frees up CylLS″ which is 
then able to activate the cytolysin complex.  
We believe that the Pld peptides are also able to form complexes with 
each other, which contributes to their specialized activity despite similarity in 
structures.  We present a model in which the Pld peptides are forming complexes 
for bioactivity and increased stability of PldA1 and PldA3. When PldA1 and PldA3 
are in complex together, inhibition of sensitive cells and upregulation of the locus 
is able to occur. Although PldA2 was not recovered and bioactivity of PldA2 is 
 78  
unknown, it is possible that PldA2 also forms a complex with PldA3 that is 
needed for signaling but not for inhibition. 
This represents a novel strategy for producing specialized, highly 
homologous lantibiotic peptides that may prove useful in the development of new 
antimicrobials. 
3.4 Materials and Methods 
Bacterial strains, plasmids, and growth conditions. 
All pneumococcal strains and plasmids used are described in Table 3.1. All 
primers used are described in Table 3.2..All pneumococcal strains were plated 
on either 5% sheep’s blood agar (SBA) or tryptic soy agar (TSA) plates with 0.5% 
catalase (Worthington, Lakewood, NJ) (4,741 U) and incubated at 37°C with 5% 
CO2. For growth in liquid culture, all pneumococcal strains were grown in Todd-
Hewitt broth supplemented with 0.5% yeast extract (THY). Antibiotics were 
added when indicated in the following amounts: 500 μg/ml kanamycin and 100 
μg/ml streptomycin. Escherichia coli strains were grown in Luria-Bertani (LB) 
broth or LB agar and supplemented with 50 µg/ml of kanamycin when indicated. 
Table 3.1. List of strains and plasmids used. 
Strain Description Source 
P174 Clinical isolate from South Africa,  
contains pld locus; ErmR, ChlR, NeoR 
 
[93] 
P174act P174 containing a single base pair 
mutation T->C in the intergenic region 
upstream of pldF 
[136] 
 
P174strepR P174 backtransformed with  
lysates of a strepR strain to confer strep  
resistance 
 
P174pldM-lacZ P174 with lacZ fused to pldM and used 
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as reporter to detect the presence of 
exogenous peptides 
TGR4 Pld sensitive strain 
P174pldA1-4::Janus P174 with Janus replacing  
peptide region of the pld locus; KanR, 
StrepS 
P174pldA1pldA2::Janus P174 with Janus replacing pldA1pldA2 In this 
study 




P174pldA1+/∆pldA2::pldA1 P174 containing a pldA1 duplication in 
place of pldA2 
In this 
study 
P174∆pldA1∆pldA2 P174 containing a deletion of 
pldA1pldA2 along with the intergenic 
region between pldA1 and pldA2 
In this 
study 
P174act∆pldA1∆pldA2 P174act containing a deletion of 
pldA1pldA2 along with the intergenic 
region between pldA1 and pldA2 
In this 
study 
Plasmids Description Source 
E115 pCR2.1 TOPO vector containing the 
pldA1-4 region with pldA1 deleted using 
inverse PCR 
[136] 
E123 pCR2.1 TOPO vector containing the 
pldA1-4 region with pldA2 deleted using 
inverse PCR 
E186 pCR2.1 TOPO vector containing 500bp 
up and downstream of pldA1-4 region 
but with pldA1pldA2 deleted 
In this 
study 
E187 pUC57 containing pldA1 duplication in 
place of pldA2 along with 500bp 




Table 3.2 List of primers used. 
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of Janus 
cassette and 









4 5’-GAGAAGTGTTGTTTTTCCAC-3 Reverse 





Construction of pldA1 duplication and pldA1pldA2 deletion strains 
 To create a duplication of pldA1, a strain containing a Janus cassette replacing 
pldA1 and pldA2 was made first. The Janus cassette contains a kanamycin 
resistance marker (kan) and a counterselectable rpsL+ marker and is used as 
genetic tool to construct allelic replacements. P174 pldA1pldA2::Janus was made 
by digesting plasmid E115 and E123 with SmaI. E115 contains the pldA region 
along with 500bp up and downstream DNA and has a pldA1 deletion that was 
created through inverse PCR and contains a SmaI site in between the start and 
stop codon of pldA1. E123 is like E115 but pldA2 has a SmaI site in between 
start and stop codon. Both plasmids were digested with BamHI and SmaI site. 
The digest released product from E123 was used to ligate into the digested 
plasmid E115 so that the upstream region of pldA1 was included and the 
intergenic region between pldA2 and pldA3 creating plasmid E186. The Janus 
cassette from P174 pldA1-4::Janus was amplified using primer pair 1 and 2  
adding a SmaI site on either end of the Janus.  The SmaI digested Janus and 
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E186 were ligated together and transformed into P174strepR creating P174 
pldA1pldA2::Janus. 
A DNA fragment of 1500bp was synthesized by GenScript containing 
500bp upstream of P174’s pldA1 and 500bp downstream of pldA2. The ORF 
encoding pldA2 was replaced with pldA1 and the intergenic region between 
pldA1 and pldA2 was unchanged. This DNA fragment contained two copies of 
pldA1 and was ligated into pUC57 creating E187. The resulting plasmid E187 
was transformed into P174 containing a Janus cassette replacing both the pldA1 
and pldA2 genes.  Allelic replacement of the Janus was confirmed with primer 
pair 3 and 4. 
 For construction of the pldA1pldA2 deletion, plasmid E186 was 
transformed into either P174pldA1pldA2::Janus or P174actpldA1pldA2::Janus. 
Confirmation that the Janus cassette had been replaced was determined with 
primer pair 3 and 4 as well as sequencing. 
Inhibition and signal secretion overlay assays 
Overlays assays used to detect inhibition and signaling were performed as 
described previously [133].  
Organic resin extraction 
Since Pld peptides are only expressed when grown as stabs on agar 
plates, a biphasic growth system was used for purification.  P174act was stabbed 
into plates and 30ml of growth media, THY, was overlaid on top of the plates. 
Following incubation overnight at 37 °C and 5% CO2,  media was collected and 
centrifuged. Supernatants were filtered sterilized using a 0.22 µm size filter. XAD-
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16 resin was added to supernatants to extract organic material from the media 
and incubated with shaking overnight. Three sequential washes ranging in 
polarity, starting with 80% methanol, ethanol with 0.1% TFA, and propanol were 
used to elute lantibiotic peptides from the resin. Washes were collected and dried 
using a rotary evaporator and pH was maintained between 4 and 5. Dried 
extracts were then resuspended in DMSO at a concentration of 20 mg/ml. Two 
fold serial dilutions were made in DMSO and 5µl spots were made on plates 
containing a lawn of a sensitive strain, P250, or a reporter strain, P174pldM-lacZ, 
that responds to exogenous Pld peptides along with X-gal. 
HPLC analysis of Ethanol fraction 
After determining that ethanol with 0.1% TFA contained the highest 
specific activity, fractions were dried down using a rotary evaporator. The dried 
fraction was dissolved in HPLC grade methanol at a concentration of 50 mg/µl 
and 50 µl was injected into the HPLC using a reverse phase Luna 5 µm C8 (2) 
100 Å 50 × 1.0 mm column. The solvent used was H2O with 0.1% TFA (A) and 
acetonitrile with0.1% TFA (B). A linear gradient of 30% to 40% of solvent B in 53 
minutes at a flow rate of 6 ml/min was used for separation. To identify peaks that 
contained possible Pld peptides, fractions collected from a isogenic nonproducer 
strain, P174∆pldK, was also analyzed.  Peaks present in the chromatogram of 
P174act but absent chromatogram of P174∆pldK were chosen for bioactivity 
analysis. Peaks collected were dried down and dissolved in DMSO at a final 
concentration of 0.1mg/µl. Samples were tested by pipetting 5µl on plates 
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containing a lawn of a sensitive strain, P250, or a reporter strain, P174pldM-lacZ, 
that responds to exogenous Pld peptides along with X-gal. 
MS/MS and NMR 
Mass spectrometric analysis of extracts was performed using an Agilent 
6520 Q-TOF mass spectrometer equipped with an Agilent 1290 HPLC system, 
maintained at the University of Michigan core facility in the Department of 
Chemistry. LC for mass spectrometry was conducted using Luna 5 µm C8 (2) 
100 Å 50 × 1.0 mm column and a solvent system of methanol (w/ 0.1% FA) and 
H2O (w/ 0.1% FA) at flow rate of 0.3 mL/ min with linear gradient from 30% B to 
90% B in 11 min. Preliminary LCMS analysis of HPLC fractions was performed 
on a Shimadzu 2010 EV ESI spectrometer.   
All NMR spectra were acquired on a Varian INOVA 600 MHz at the NMR 
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Streptococcus pneumoniae is subject to competitive interactions in the 
nasopharynx. Since colonization is a prerequisite for pathogenesis, 
understanding the competitive interactions of pneumococcus among other co-
colonizing bacteria is important in identifying factors that enhance the likelihood 
of a successful colonization. One factor important in pneumococcal competition 
is the production of antimicrobial peptides. The Blp and Cib peptides are two 
well-described examples of unmodified bacteriocins that pneumococcus secretes 
to eliminate competitors [90, 93, 96, 106]. Additionally, production of the Blp 
peptides is upregulated when competence is initiated, indicating that, in addition 
to removing competitors, DNA released during bacterial lysis can be used for 
recombination [140, 141]. Together these activities, the elimination of competitors 
and subsequent uptake of DNA, has made pneumococcus a successful, 
adaptable pathogen. Although vaccines and antibiotics are used to remove the 
more pathogenic pneumococcal strains from the population, this has only 
provided an opportunity for other pneumococcal strains to colonize and cause 
disease [84].  
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Possible alternatives that are being investigated for eradicating pathogenic 
bacteria include the use of a modified bacteriocin or lantibiotic. Unlike umodified 
bacteriocins, lantibiotics undergo posttranslation modifications that make them 
resistant to proteolytic degradation, thermal inactivation, and provide stability at 
low pH [142]. These biochemical properties make them useful to pursue as a 
therapeutic.  Therefore, we became interested in finding a lantibiotic that would 
demonstrate potent anti-pneumococcal activity. Although several lantibiotic loci 
have been described in pneumococcus, none have been associated with 
antimicrobial activity until recently.   
My thesis work has been  centered around characterizing the 
pneumococcal lantibiotic, pneumolancidin (pld), secreted by P174 using a 
comprehensive approach that involved careful genetic and biochemical 
dissection of the function of genes in the locus, described in chapter II and III, 
respectively. The pld  locus had broad spectrum inhibitory activity, including the 
ability to kill 54 out of 55 pneumococcal strains, making it an attractive candidate 
for future development as a therapeutic.   
Notably, four homolgous pld peptides were found in tandem. A single 
modification enzyme encoded by the gene pldM was also found on the locus. 
The presence of a single modification enzyme with multiple lantibiotic peptides is 
different from the previously described two peptide lantibiotics. For most two 
peptide lantibiotics, two different modification enzymes are encoded that 
separately modify each peptide [28]. The sequence homology between the 
LanA1 and LanA2 is typically low, and therefore, the requirement for two different 
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LanM  enzymes, LanM1 and LanM2, is necessary to have both peptides properly 
modified [28, 57]. After processing and cleavage, the peptides are functional 
yielding Lanα and Lanβ. As expected, the structures of Lanα and Lanβ are 
different from each other and are required for their specific role in inhibition of 
sensitive strains. Lanα typically resembles type-B lantibiotics like mersacidin, and 
binds to lipid II, an important bacterial cell wall precursor. Lanβ resembles type-A 
lantibiotics like nisin, and forms pores upon recognition of the complex between 
Lanα and lipid II [30]. In other multipeptide lan systems in which a single lanM is 
encoded in the locus, the lan peptides are identical in sequence suggesting 
similar structures with redundancy in the peptide’s function.  The pld locus did not 
express the same characteristics as of other multipeptide lantibiotic systems that 
have been described. Rather than expressing several identical peptides, the 
amino acid sequences of PldA1-4 were found to be similar but not identical in the 
context of a signle  pldM gene, indicating that there might be discrete functions of 
these Pld peptides. 
Since lantibiotic peptides are known to function as both antimicrobials and 
as autoinducers, the aim of my dissertation was to dissect the individual the roles 
of the putative Pld peptides A1-4 using both a genetic approach (chapter II) and 
a biochemical approach (chapter III). 
 
The role of the pld peptides 
In the WT setting, it was found that PldA1-3 were each required for 
signaling with the exception of PldA4 (Fig. 2.2).. This suggested that Pld peptide 
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A1-3 were each required for upregulation of the locus, perhaps forming a 
complex that is recognized by the histidine kinase, PldK. The requirement for 
complex formation for signaling is unprecedented in other lantibiotic systems.  
Luckily, a serendipitous mutant of P174 was discovered which was 
characterized by a lowered threshold for activation of the pld locus (Fig.2.4). A 
single base pair mutation was found in the intergenic region between pldA4 and 
pldF that resulted in downregulation of the immunity transporter presumably due 
to the disruption of the -10 RNA polymerase binding site, leading to activation of 
the pld locus at lower peptide concentrations (Fig. 2.3). Peptide deletions were 
assayed in this background and found to have distinct phenotypes (Fig 2.2). 
PldA1 was implicated in inhibition, PldA2 was found to be dispensable for 
inhibition and signaling, and PldA3 was required for signaling and possibly for 
inhibition (Fig 2.2). 
While the peptide deletions in the P174act background helped to provide 
clues as to the function of each of the Pld peptides in signaling, we sought to 
purify the individual peptides to clarify the specific role of each peptide in both 
signaling and inhibition. We also wanted to assess the bioactivity of purified Pld 
peptides and elucidate their stuctures. Using HPLC, we were only able to purify 
PldA1and PldA3. Based on our genetic studies, we predicted that PldA1 would 
kill sensitive strains and PldA3 would be the autoinducer although data from the 
wildtype strains suggested complex formation was likely to be vital.  The activities 
of purified PldA1 and PldA3 were somewhat surprising. A preparation of 
PldA1only had evidence of signaling but not inhibition, while a preparation of 
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PldA3 only had evidence of inhibitory activity but not signaling.   Both 
preparations were active only at very high concentrations that are unlikely to be 
physiologic. 
One explanation for difference in activity between purified Pld peptides 
and the phenotypes of the peptide deletion strains, might be that PldA3 helps to 
stabilize PldA1 and PldA2 through formation of a complex. In the absence of 
PldA3 inP174act, signaling is abrogated even in the presence of PldA1which was 
found to signal in its purified form (Fig 2.2 & 3.3). If PldA1 is unstable without 
PldA3, it would make sense that P174act∆pldA3 is unable to signal or inhibit. 
PldA1 is unstable and cannot upregulate the locus including expression of PldA3, 
which is needed for inhibition. In summary, PldA3 is necessary for signaling and 
requires the presence of either PldA1 or PldA2 presumably through the formation 
of a complex which stabilizes PldA2 and PldA1. When PldA3 and PldA1 are 
expressed by P174act, inhibition occurs (Fig 2.2). In contrast, expression of 
PldA3 and PldA2 does not result in inhibitory activity (Fig. 2.2). This suggests 
that PldA2 is not as important for inhibition compared to PldA1. This is surprising 
because of the high sequence similarity between PldA1 and PldA2, differing by 
only two amino acids. Specifically, T19S, is involved in the formation of a 
methyllanthionine ring in PldA1 which would be replaced by a lanthionine ring in 
PldA2. This may account for their difference in activity. However, since PldA2 
was not purified, we cannot state this with certainty nor determine the function of 
PldA2 directly. Supernatants that were collected from biphasically grown P174act 
were able to signal and inhibit months after being collected suggesting that either 
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having all the Pld peptides together is important for stability or that the crude 
preparation has other stabilizing factors. Additionally, when concentrating 
supernatants it was noted that activity was retained above a 50kDa cut off 
column.   This suggests that the Pld peptides are forming complexes of very high 
molecular weights. To support the theory of a complex being formed between 
PldA1 and PldA3 that is needed for stability, purified PldA1 and PldA3 will be 
combined and tested for signaling and inhibition over time as compared to Pld 
peptides alone. If complex formation is needed, then we should expect to see 
bioactivity over longer periods of time and more potent inhibition than PldA1 or 
PldA3 alone.    
Another explanation for the lack of inhibition seen in P174act∆pldA1 could 
be that a complex is formed between PldA2 and PldA3, which is needed for 
signaling but not for for inhibition. This would be reminiscent of the cytolysin 
system in which both peptides form a complex that is inactive. In the presence of 
target cells, the larger subunit is able to bind to eukaryotic membranes freeing up 
the smaller peptide that is able to activate the cytolysin locus [60-62]. In strains 
expressing only PldA3, inhibitory and signaling activity were abrogated which 
provides evidence in support of PldA3 most likely forming a complex under in 
vivo conditions that is needed for signaling or inhibition if in complex with PldA1 
(Fig. 3.1).  
All of this data seems to suggest that the role of the Pld peptides is more 
complex than originally expected and represents a unique strategy for 
specialization of function described for lantibiotic peptides. Interestingly, the 
 90  
structures of PldA1 and PldA3 both contained globular domains on opposite ends 
of the peptides, and both had different bioactivity. It can be hypothesized that 
PldA2 most likely resembles PldA1 structurally and yet is not as important for 
inhibitory activity as compared to PldA1. This indicates that the two amino acids 
that are different between PldA1 and PldA2 are enough to confer  specificity 
although site directed mutagenesis will have to be done to verify this hypothesis. 
The sizes of the Pld peptides were found to be smaller than predicted and 
the cleaved N-terminal portion was identified in culture supernatants after HPLC 
separation (Fig. 3.3).  These data suggest that a secondary cleavage event is 
occurring after removal of the N-terminal leader peptide by PldT. It is possible 
that the secondary cleavage event is an artifact of the purification process and is 
contributing to the instability of the peptides. The pld locus does not encode an 
additional protease in addition to PldT but it may be able susceptible to another 
protease for secondary cleavage. This has been described in other lantibiotic  
systems [17]. To answer this, genomic sequencing of P174 is underway to 
identify possible proteases. Additionally, to show that secondary processing is 
occurring in vivo, LAESI-MS will be used to detect the presence of doubly 
processed Pld peptides in the halos surrounding stabbed P174 in the inhibition 
overlay assay. This will also provide verification that the purification process is 
not responsible for the secondary cleavage of the lantibiotic peptides. 
 
The role of the immunity transporter in regulation of pld locus 
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It is interesting and counterintuitive that decreased expression of an 
immunity ABC transporter needed for protection against the Pld peptides leads to 
an increase in the activation of the pld locus (Fig 2.4). In a WT background, it 
was shown that expression of pldFE is upregulated in response to exogenous 
Pld peptides which is absent in the P174act background following induction (Fig 
2.4).  One possible theory to explain how decreased expression of PldFE lowers 
the threshold for signaling of the pld locus is that PldFE may interact with PldK to 
initiate upregulation of the pld locus upon binding of exogenous pld peptides.  
Some preliminary data that suggest that PldFE is involved in signaling is 
the fact that a deletion of pldFE resulted in a strain with a loss of inhibition and 
signaling activity. If PldFE was involved in immunity alone, then a deletion of 
pldFE should have resulted in a lethal mutation and no transformants should 
have been recovered. However, P174∆pldFE was easily constructed.  The lack 
of transcriptional activity in this strain suggested that the pld locus is 
transcriptionally inactive either because of the essential role of PldFE in signaling 
or because a secondary mutation arose preventing the locus from being 
upregulated. If a secondary mutation is responsible for inactivity of the locus, 
sequencing of the entire pld locus in P174∆pldFE will reveal a secondary 
mutation and perhaps details regarding the role of the mutation on the regulation 
of the pld locus. Instead of sequencing, complementation of pldFE can also be 
utilized to determine if activity can be restored with an ectopic copy of the 
transporter gene.  
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In other lan systems, immunity is mediated by two proteins [63, 73]. One 
being the immunity transporter, LanFEG, which is thought to act as an efflux 
pump to remove lantibiotic peptides from the membrane [63]. The second 
immunity protein is a lipoprotein, LanI, that binds to the lantibiotic and prevents it 
from interacting with the membrane [70, 73]. In the pld locus, we found a small 
ORF predicted to encode PldI downstream of pldA4 (data not shown). To verify 
the role of PldI, a clean deletion of pldI was constructed and assayed for 
immunity. An immunity defect was observed in ∆pldI suggesting that PldI is 
involved in conferring immunity. This provides evidence that a deletion of PldFE 
may not result in a lethal mutation because of the presence of a second immunity 
protein, PldI. There is still an immunity defect even with deletion of either PldFE 
or PldI and this suggests that full immunity is reached with expression of both 
immunity proteins. In chapter II, it was shown that Streptococcus mitis is immune 
to P174 most likely because it has a region with high homology  to PldKR and 
PldFE (Fig. 2.1 & Table 2.1). After discovery of PldI, we reviewed the locus in 
S.mitis  and found it also contains pldI and the putative promoter sequence 
driving expression of pldI which means that minimal requirement for immunity is 
expression of the two component system, PldKR, and both immunity proteins, 
PldFE and PldI. It is possible other strains encode the same region to ensure 
immunity against Pld.   
 
Further evidence supporting the theory that PldFE may interact with PldK 
is the homology between PldFE and a family of ABC transporters that mediate 
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antibiotic resistance, BceAB-type. In a homologous system, Bacillus subtilis 
expresses a bacitracin immunity transporter, BceAB, that confers protection by 
binding to bacitracin, a cyclic antimicrobial peptide [124]. The binding of BceAB  
to bacitracin is recognized by the histidine kinase, BceS, which increases 
transcription of the bacitracin immunity transporter [124]. Given the homology, it 
is possible that PldFE might also be involved in signaling in a similar way by 
forming a sensory complex with PldK. We hypothesized that since expression of 
the two component system PldKR is not differentially upregulated in response to 
exogenous Pld peptides its levels likely remain constant. Altering the levels of 
PldFE may change signaling dynamics by either increasing or decreasing the 
likelihood of the two complexes finding each other. In the P174act background, 
less PldFE is expressed. When exposed to equal amounts of basal Pld peptides, 
the strain producing less PldFE will have a greater percentage of PldFE/Pld 
peptide complex to interact with and activate PldK. In the case of P174, since 
there is more PldFE than PldK, a greater proportion of PldFE does not have Pld 
peptides bound and fails to activate PldK at low peptide concentrations. This 
mechanism may also be a way to limit uncontrolled upregulation of the pld locus. 
At high exogenous Pld peptide levels, which have saturated PldFE binding 
resulting in PldK activation, upregulation of the pldFE operon occurs ensuring 
that the ratio of bound to unbound PldFE prevents further activation of PldK. 
Future experiments should be performed to verify that PldFE can form a sensory 
complex with PldK by peforming pull-down assays. Since the expression level of 
PldFE has been deduced using reporter fusions, it would be useful to confirm at 
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the protein level that downregulation of PldFE is occurring in P174act. Also, 
altering the expression of PldFE using an inducible construct would be helpful in 
determining if changing ratios of PldFE to PldK levels is sufficient to recapitulate 
the lowered threshold requirement for signaling. Ultimately, manipulation of 
PldFE might help increase output of Pld peptides and facilitate purification.  
An alternative explanation for how levels of PldFE might affect regulation 
of the pld locus is by sequestering of Pld peptides. Immunity transporters are 
known to bind to lantibotic peptides [72]. It is possible that low levels of PldFE 
frees up Pld peptides which are then able to interact with PldK . Therefore, less 
Pld peptides are needed for activation of the pld locus. This explanation would fit 
if the reason for inactivity of the pldFE KO is attributable to a secondary mutation. 
 
Advantages of having a functional pld locus 
With the homology shared between PldFE and BceAB, it would be 
interesting to assay P174’s resistance to cyclic antimicrobial peptides such as 
bacitracin and nisin. Cross protection to other antimicrobial peptides mediated by 
PldFE could also be a reason for the maintenance of the pld locus in 
pneumococcal strains. In chapter II, a pneumococcal strain, P130, was identified 
as the only strain immune to Pld peptides. Although it has immunity, inhibitory 
activity was not seen in this strain due to a mutation disrupting the function of 
PldM indicating that P130 is a cheater strain (Fig. A4). This also suggests that 
producing Pld peptides is energetically costly and instead of inactivating the 
entire locus, immunity is retained. However, other pneumococcal strains were 
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found that carry the pld locus but are not immune suggesting that the locus is 
inactive. Why do pneumococcal strains retain an inactive pld locus? It is possible 
that there are other advantageous cargo genes carried on the same ICE as the 
pld locus that are transmitted between strains.  
After screening over 400 pneumococcal strains, only P174 has been 
shown to have Pld-mediated antimicrobial activity. Using a mouse model of 
staggered colonization, we demonstrated that having a functional pld locus 
confers a competitive advantage in invading a previously colonized surface. An 
interesting potential use of a strain that produces anti-pneumococcal antibiotic 
would be as a probiotic strain to prevent other pathogenic pneumococcal strains 
from colonizing. Inoculation of a Pld peptide expressing probiotic would be most 
beneficial in populations that are at high risk of acquiring pneumococcal disease. 
Currently, lantibiotic expressing strains are being developed for use as a 
probiotic in the oral cavity, preventing other Streptococcus mutans from 
colonizing. However, additional experiments would be needed to verify the 





Pneumococcus, a member of the diverse microbial community in the 
nasopharynx, is able to compete with other strains by secreting bacteriocins. 
Understanding the dynamics of bacterial competition will help to predict which 
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pneumococcal strains will dominate in the population. Since colonization is a 
prerequisite for pathogenesis, those strains able to dominate are more likely to 
cause disease. One way to combat these pathogenic strains is the use of 
bacteriocins ,specifically lantibiotics.  
There are many advantages to using lantibiotics in treating bacterial 
infections. Lantibiotics have attractive biochemical properties that make them 
desirable as therapeutics. Additionally, lantibiotic production is a common 
strategy used in competition and therefore, has evolved to be highly effective 
against bacteria. The food industry has benefitted from the use of lantibiotic 
producing strains by adding them directly to food to prevent spoilage and 
colonization by pathogenic bacteria. Nisin, a well characterized lantibiotic, has 
been used in the food industry for the past 50 years without generating any nisin 
resistant strains. Therefore, we were interested in finding a potent anti-
pneumococcal lantibiotic that could ultimately be used as therapeutic. 
We found that a clinical isolate of S. pneumoniae secretes a lantibiotic, 
pneumolancidin, that exhibits unprecedented broad spectrum antimicrobial 
activity. With the exception of the pld encoding strain, P130, we have not yet 
identified an isolate of S. pneumoniae that is immune or resistant to the 
pneumolancidin producing strain.  The locus encoding pneumolancidin was of  
unique interest because it contained a tandem array of four genes encoding the 
structural peptides.  My dissertation was focused on dissecting the role of each of 
the Pld peptides. In both chapters II and III, the interaction and function of these 
Pld peptides were shown to be more complex than originally predicted. The 
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discovery of the pld locus in several pneumococcal strains represents a unique 
strategy for competition. Our studies involving the Pld peptides will shed further 
light into how bacteria are able to shape the microbial community through 
production of these antimicrobial peptides. Additionally, a greater understanding 
of the function and structure of these Pld peptides will also aid in the 
development of future antimicrobials to combat pneumococcal infections. 
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APPENDICES 
  




Supplemental figures for Chapter II. 
 
 
 100  
Table A1. Description of pneumococcal and streptococcal strains used in 
inhibition overlay assays. 
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HSC5 Emm 14.0 Y [143] 
SF370 Emm 1.0 Y [144] 
MEW18 Emm 89.0 Y MEW 
MEW19 Emm 28.0 Y MEW 
MEW20 Emm 1.45 Y MEW 
JRS4 Emm 6.0  Y [145] 
MGAS166 Emm 1.0 Y [146] 
MEW34 Emm 161.0 Y MEW 
MEW62 Emm 4.0 Y MEW 
MEW96 Emm 89.0  Y MEW 
MEW97 Emm 118.0 Y MEW 
SLC826 Emm 28.0 Y MEW 
Streptococcus 
agalactiae 
ATCC12386  N  
ATCC12403 III Y  
UMMC GBS 
632 
Clinical isolate Y BF 
A909 Ia N [147] 
COH1 III N [148] 
DK14 Ib N [149] 
DK23 II Y [149] 
TIGR 18RS21 II Y [147] 
CNCTC 1/82 IV N [150] 
JM9 VIII N [151] 
TIGR H36B IB Y [147] 
NT-6 VI N [152] 
H1A  Ia N BF 
 105  
87-603 VII Y [151] 
ATCC BAA 
611 
V N [147] 
MEW= Michael E. Watson’s personal collection 
BF= Betsy Foxman’s personal collection 
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Collection Strain Serotype ST aroE gdh gki recP spi xpt ddl Accession 
number 
South 
African   
174 23F 6279 15 29 4 21 30 1 5 KT630265 
130 6B 6389 7 25 8 5 10 6 14 KT630266 
Clinical 
isolates 
A74 6B 2452 7 2 8 5 10 6 14  
B56 NT 448 8 5 2 27 2 11 71  
B59 NT 448 8 5 2 27 2 11 71  
D69 NT 448 8 5 2 27 2 11 71  
Genome 
sequenced 
PN1 6A 7151 7 13 8 6 6 6 494 ERR163220 
BHN418 6B 138 7 5 8 5 10 6 14 ASHP01000000 
MNZ14 NT 448 8 5 2 27 2 11 71 ASJO01000000 
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Table A3. Strains and plasmids used in this study. 
Strains Description Reference or source 
P174 Clinical isolate from South 
Africa, contains lan locus; 
ErmR, ChlR, NeoR 
[93] 
P130 Clinical isolate from South 
Africa, contains 
nonfunctional lan locus 
[93] 
P537 Serotype 6A with Janus 
replacing blpT to 
upstream of blpY  
[93] 
P1535 D39 with Janus inserted 
in comD  
[125] 
P147 Clinical isolate from South 
Africa, belongs to the 
same MLST as P174 but 
does not contain the lan 
locus 
[93] 
P650 R6 strain with StrepR  
P174 strepR P174 backtransformed 
with lysates of P650 to 
confer strep resistance 
In this study 
P174 pldA1-4::Janus P174 with Janus 
replacing peptide region 
of the pld locus; KanR, 
StrepS 
In this study 
P174 ∆pldK P174 with Spec cassette 
inserted in pldK 
In this study 
P174 ∆pldT P 174 with Spec cassette 
inserted in 3’ ABC 
transporter 
In this study 
P174 ∆pldM P174 with Spec cassette 
inserted in lanM 
In this study 
P174 ∆pldA1 P174 with deletion of 
pldA1; StrepR 
In this study 
P174 ∆pldA2 P174 with deletion of 
pldA2; StrepR 
In this study 
P174 ∆pldA3 P174 ∆peptide 2; StrepR In this study 
P174 pldA1-4EF::Janus P174 strepR with Janus 
replacing pldA1-4 and 
pldFE; Streps KanR 
In this study 
P174act P174 containing a single 
base pair mutation T->C 
in the intergenic region 
upstream of pldF 
In this study 
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P174act ∆pldA1 P174 act containing in 
frame deletion of pldA1 
In this study 
P174act ∆pldA2 P174 act containing in 
frame deletion of pldA2 
In this study 
P174act ∆pldA3 P174 act containing in 
frame deletion of pldA3 
In this study 
P174act pldM-lacZ P174act plasmid 
integration of E110 used 
as a reporter to test for 
the presence of active 
exogenous peptides 
In this study 
 
P174 ∆pldFE P174 with pldFE deletion, 
StrepR 
In this study 
P174 ∆pldA1-4 pldM-
lacZ 
P174 pldA1-4::spect  with 
pldM-lacZ fusion 
In this study 
P174 pldM-lacZ P174 plasmid integration 
of E110 used as a 
reporter to test for the 
presence of active 
exogenous peptides 
In this study 
P174 pldF-lacZ P174 with pldF fused to 
lacZ as result of 
intergration of E181,;KanR 
In this study 
P174 PactpldF-lacZ P174 with plasmid 
integration of E182 
resulting in the lacZ being 
fused to the promoter of 
pldF including the 
mutation from P174 act; 
KanR 
In this study 
P174 act P174pldF-lacZ P174 act with plasmid 
integration of E181 
resulting in P174’s 
promoter of pldF  fused to 
lacZ ; KanR  
In this study 
P174 PpldA1-lacZ P174 with plasmid 
integration of E188 
resulting in promoter of 
pldA1 fused to lacZ ; KanR 
In this study 
P174act PpldA1-lacZ P174act with plasmid 
integration of E188 
resulting in promoter of 
pldA1 fused to lacZ;  KanR 
In this study 
Plasmids Description Source 
E65 pEVP3 with kanR   In this study 
E68 pUC19 with In this study 
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spectinomycin cassette 
inserted in place of 
ampicillin 
E93 TOPO vector with pldA1-4 
+ 500 bp upstream and 
downstream of P174 
cloned into MCS ; KanR 
In this study 
E97  500 bp middle region of 
pldT cloned into TOPO 
vector using primers 17 
and 18 
In this study 
E98 500 bp middle region of 
P174 pldK cloned into 
TOPO vector using 
primers 15 and 16 
In this study 
E102 E68 with P174 pldK 
middle region cloned in 
MCS using EcoRI 
In this study 
E103 E68 with P174 pldT 
cloned into MCS using 
EcoRI 
In this study 
E105 Inverse PCR on E93 with 
primers 3 and 4 creating 
full deletion of pldA1-4 
and unique SmaI site 
In this study 
E110 E65 with PCR fragment of 
primer pair 24 and 25 
cloned upstream of lacZ, 
reporter plasmid; KanR 
In this study 
E181 pEVP3 with P174’s pldF 
fused to lacZ, KanR 
In this study 
E182 pEVP3 with P174 act’s 
pldF fused to lacZ, KanR 
In this study 
E188 pEVP3 with pldA1 fused 
to lacZ, kanR 
In this study 
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Table A4. Primers used in this study. 
Prime
r # 
Primer Sequence Description 
1 
 









Forward primer for full peptide 




Reverse primer upstream of 




Forward primer to amplify janus 




Reverse primer to amplify janus 




Forward primer used for 




Reverse primer used for 





Forward primer used for 




Reverse primer used for 





Forward primer used for 





Reverse primer used for 





Forward primer used for 





Reverse primer used for 
inverse PCR to delete peptide 
4 
15 5’-TGTCCTTGTTTACGTCTTTC-3’ Forward primer to amplify 
middle of P174 lan histidine 
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kinase 
16 5’-TGAAATTTTTTATCGCCATC-3’ Reverse primer to amplify 
500bp of P174 histidine kinase 
17 5’-AAAGAATTTGGAACAAAAAA-3’ Forward primer used to amplify 
500 bp middle region of 3’ ABC 
transporter 
18 5’-CAATGCCAATTTGTTGACGA-3’ Reverse primer used to amplify 
500 bp middle region of 3’ ABC 
transporter 










Reverse primer upstream of 
first ORF of 5’ ABC transporter 




Forward primer downstream of 
second ORF of 5’ ABC 




Forward primer that anneals to 




Forward primer anneals to 
response regulator 207 bp 





Reverse primer used to amplify 
lanM 38 bp from ATG adding a 
XbaI site 
26 5’-TCAAAAATAATTCGCGTCTG-3’ Reverse internal primer of lacZ 
27 5’- ATGAATATGAGCTACAGAAC-3’ Forward internal primer of pldM   
28  5’- CGGGCATTAAAATCAATACT-3’ Reverse internal primer of pldM 
29 5’-GAAGCATCTTTAAAATCTGT-3’ Forward primer that anneals to 
peptide region found in ATCC 
700669 
30 5’-CGGATTTAAATATTTGCTAC-3’ Reverse primer that anneals to 
peptide region found in ATCC 
700669 
31 5’-GAAACTTGCACGATTTACTC-3’ Forward primer that anneals to 
peptide region found in P174 
32 5’-TGCCATGAGTATTTTGTGCA-3’ Reverse primer that anneals to 






Forward primer that anneals 19 
bp downstream of the site of 
the hyperinducible mutation 
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and contains a NsiI restriction 
site 







Forward primer of site directed 
mutagenesis deleting CCGT 
from intergenic region 






Reverse primer of site directed 
mutagenesis deleting CCGT 
from intergenic region 






Forward primer used to 
construct pldK-lacZ reporter, 
anneals 451 bp upstream of 







Reverse primer used to 
construct pldK-lacZ reporter, 
anneals 15 codons downsteam 







Forward primer used to 
construct pldF-lacZ fusion, 
anneals 11bp upstream of 






Reverse primer used to 
construct pldF-lacZ fusion, 
anneals  15 codons after start 
codon of pldF and adds XbaI 
site 
41 5’-GTACAATTTCTTGAAACAAGCC-3’ Forward primer that anneals 
approximately 500bp upstream 
of second BsrGI site 
42 5’-CGCTCTTTGTCAAGATATTC-3’ Reverse primer that anneals 
approximately 500bo 







Forward primer that anneals to 







Reverse primer used to amplify 




Forward primer that anneals 
165 bp upstream of second 
 113  
BsrGI site in lanM 
46 
 
5’-AGAATAGCCTAAAATAGAAT-3’ Reverse primer that anneals 
700 bp downstream of second 




Forward primer used to create 
pldA1-lacZ fusion that anneals 
460 bp upstream of start codon 




Reverse primer used to create 
pldA1-lacZ fusion that anneals 
37 bp after start codon of pldA1 
and adds a XbaI site 
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Figure A1. Lantibiotic Peptides Detected by Reporter Strain P174 pldM-lacZ 
and P174 ∆pldA1-4 pldM-lacZ. P174 was stabbed into a TS plates and 
incubated for approximately 6 hours. Overlays were prepared with the 
chromogenic substrate, X-gal, included in the overlay mixture with either reporter 
strain both containing a pldM-lacZ fusion with intact peptides or the same 
reporter but lacking all four structural peptides. 
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Figure A2. Inhibitory and signaling activity of pldK and pldF reporters.  
A)To confirm that the reporter constructs of pldK and pldF in either P174 or 
P174act backgrounds retained a functional pld locus, reporters were stabbed into 
TSA plates and overlayed with either a senstive strain for inhibition, or with the 
reporter, P174pldM-lacZ for signal secretion. B) The pldK reporter strains of 
either P174 or P174act was used as the overlay strain over stabbed P174 and 
assessed for their ability to respond to signal.
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Figure A3. Paired relative ratios of invaders to resident.  CFU/ml of the 
invader strain, P174 or P174∆pldA1-4, was compared to the CFU/ml of the 
resident strain, P174∆pldK, to calculate a relative ratio between strains in a 
single nasal wash. A relative ratio of 1 indicated by a line denotes equal 
colonization by the two strains. A relative ratio greater than 1 indicates more 
invader than resident strain. Statistical analysis was performed using unpaired 
Mann-Whitney test. *=p<0.05. 
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Figure A4. Inactivity of pld locus in P130 linked to mutation in PldM. A) 
Amino acid alignment of PldM of P130 and P174 in the area of interest is shown. 
Amino acids that are conserved in a zinc binding domain of PldM are shown in 
red. P130 has a tyrosine in place of the conserved cysteine. B) Overlay assays 
demonstrating inhibition of TIGR4 were performed using strains P174, P130, and 
P174 PldM C869Y.  
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APPENDIX B 
Supplemental figures for Chapter III. 
 
Figure B1. Q-TOF ESI MS deconvoluted data for PldA3 and follow up MS/MS spectra on the most 
abundant TIC peak with m/z 2086.1496 
 119  
 
 
Figure B2. MS/MS fragmentation ions for PldA3 and the schematic representing the tertiary structure 
of PldA3. 
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Figure B3. Q-TOF ESI MS chromatogram of N-terminus cleavage of PldA3. 
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Figure B4. 1H NMR (600 MHz, DMSO-d6) spectrum of PldA3 
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Figure B5. HSQCAD NMR (600 MHz, DMSO-d6) spectrum of PldA3 with resolved and annotated 
tertiary signals. 
  
 123  
 
Figure B6. HSQCAD NMR (600 MHz, DMSO-d6) spectrum of PldA3. 
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 125  
 
Figure B8. gCOSY NMR (600 MHz, DMSO-d6) spectrum of PldA3. 
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Figure B9. ESI MS for PldA1 and follow up MS/MS spectra along with schematic representing the 
tertiary structure. 
 127  
 
 









Figure B11. HSQCAD NMR (600 MHz, CD3OD) spectrum of PldA1.  
 




Figure B12. gCOSY NMR (600 MHz, CD3OD) spectrum of PldA1.  
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Figure B13. NOESYAD NMR (600 MHz, CD3OD) spectrum of PldA1. 
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